JP2019517544A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517544A5 JP2019517544A5 JP2018564211A JP2018564211A JP2019517544A5 JP 2019517544 A5 JP2019517544 A5 JP 2019517544A5 JP 2018564211 A JP2018564211 A JP 2018564211A JP 2018564211 A JP2018564211 A JP 2018564211A JP 2019517544 A5 JP2019517544 A5 JP 2019517544A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- amino acids
- composition according
- active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims description 78
- 150000001413 amino acids Chemical class 0.000 claims description 71
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 60
- 102000007079 Peptide Fragments Human genes 0.000 claims description 49
- 108010033276 Peptide Fragments Proteins 0.000 claims description 49
- 102100029968 Calreticulin Human genes 0.000 claims description 38
- 101000793651 Homo sapiens Calreticulin Proteins 0.000 claims description 38
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 36
- 229920001184 polypeptide Polymers 0.000 claims description 35
- 210000004027 cell Anatomy 0.000 claims description 22
- 239000002671 adjuvant Substances 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 21
- 108020004707 nucleic acids Proteins 0.000 claims description 18
- 102000039446 nucleic acids Human genes 0.000 claims description 18
- 150000007523 nucleic acids Chemical class 0.000 claims description 18
- 230000002163 immunogen Effects 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 12
- 208000014767 Myeloproliferative disease Diseases 0.000 claims description 11
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 230000003308 immunostimulating effect Effects 0.000 claims description 8
- 239000002246 antineoplastic agent Substances 0.000 claims description 7
- 210000004443 dendritic cell Anatomy 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 239000013598 vector Substances 0.000 claims description 6
- 229960004528 vincristine Drugs 0.000 claims description 6
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 6
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 6
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- 125000000539 amino acid group Chemical group 0.000 claims description 5
- 238000002512 chemotherapy Methods 0.000 claims description 5
- 238000001415 gene therapy Methods 0.000 claims description 5
- 229960001438 immunostimulant agent Drugs 0.000 claims description 5
- 239000003022 immunostimulating agent Substances 0.000 claims description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- 108010063738 Interleukins Proteins 0.000 claims description 4
- 102000015696 Interleukins Human genes 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 238000009175 antibody therapy Methods 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 229940127089 cytotoxic agent Drugs 0.000 claims description 3
- -1 doxyfluridine Chemical compound 0.000 claims description 3
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 230000002335 preservative effect Effects 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims description 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 108020000946 Bacterial DNA Proteins 0.000 claims description 2
- 108010006654 Bleomycin Proteins 0.000 claims description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 2
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 2
- 102100037850 Interferon gamma Human genes 0.000 claims description 2
- 108010074328 Interferon-gamma Proteins 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 229930182555 Penicillin Natural products 0.000 claims description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 2
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 claims description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 2
- 229960004150 aciclovir Drugs 0.000 claims description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 2
- 208000017733 acquired polycythemia vera Diseases 0.000 claims description 2
- 229960003022 amoxicillin Drugs 0.000 claims description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 229960002756 azacitidine Drugs 0.000 claims description 2
- 229960002170 azathioprine Drugs 0.000 claims description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 2
- 229960001561 bleomycin Drugs 0.000 claims description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 2
- 229960004117 capecitabine Drugs 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 190000008236 carboplatin Chemical compound 0.000 claims description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 2
- 229960004630 chlorambucil Drugs 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- 229960004397 cyclophosphamide Drugs 0.000 claims description 2
- 229960000684 cytarabine Drugs 0.000 claims description 2
- 229960000975 daunorubicin Drugs 0.000 claims description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 229960001904 epirubicin Drugs 0.000 claims description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
- 229960005420 etoposide Drugs 0.000 claims description 2
- 229960000390 fludarabine Drugs 0.000 claims description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims description 2
- 235000008191 folinic acid Nutrition 0.000 claims description 2
- 239000011672 folinic acid Substances 0.000 claims description 2
- 229940047122 interleukins Drugs 0.000 claims description 2
- 229960004768 irinotecan Drugs 0.000 claims description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 2
- 229960004942 lenalidomide Drugs 0.000 claims description 2
- 229960001691 leucovorin Drugs 0.000 claims description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims description 2
- 229960004961 mechlorethamine Drugs 0.000 claims description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 2
- 229960001924 melphalan Drugs 0.000 claims description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 2
- 229960001428 mercaptopurine Drugs 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- 229960001156 mitoxantrone Drugs 0.000 claims description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 2
- 206010028537 myelofibrosis Diseases 0.000 claims description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 2
- 229960001756 oxaliplatin Drugs 0.000 claims description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 229960005079 pemetrexed Drugs 0.000 claims description 2
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims description 2
- 229940049954 penicillin Drugs 0.000 claims description 2
- 208000037244 polycythemia vera Diseases 0.000 claims description 2
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims description 2
- 229960000688 pomalidomide Drugs 0.000 claims description 2
- 208000003476 primary myelofibrosis Diseases 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 229960004964 temozolomide Drugs 0.000 claims description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 2
- 229960001278 teniposide Drugs 0.000 claims description 2
- 229960003087 tioguanine Drugs 0.000 claims description 2
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960000653 valrubicin Drugs 0.000 claims description 2
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 claims description 2
- 229960003636 vidarabine Drugs 0.000 claims description 2
- 229960003048 vinblastine Drugs 0.000 claims description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 3
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- SQQXRXKYTKFFSM-UHFFFAOYSA-N chembl1992147 Chemical compound OC1=C(OC)C(OC)=CC=C1C1=C(C)C(C(O)=O)=NC(C=2N=C3C4=NC(C)(C)N=C4C(OC)=C(O)C3=CC=2)=C1N SQQXRXKYTKFFSM-UHFFFAOYSA-N 0.000 claims 1
- 229960000908 idarubicin Drugs 0.000 claims 1
- 229940124669 imidazoquinoline Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940120975 revlimid Drugs 0.000 claims 1
- 229960004355 vindesine Drugs 0.000 claims 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 claims 1
- 229960002066 vinorelbine Drugs 0.000 claims 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 description 58
- 238000000034 method Methods 0.000 description 17
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 10
- 229960002949 fluorouracil Drugs 0.000 description 10
- 230000001939 inductive effect Effects 0.000 description 10
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 7
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- SNKDCTFPQUHAPR-UHFFFAOYSA-N 1-fluoropyrimidine-2,4-dione Chemical compound FN1C=CC(=O)NC1=O SNKDCTFPQUHAPR-UHFFFAOYSA-N 0.000 description 5
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 5
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 5
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000011510 Elispot assay Methods 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Description
æ¬çºæã¯ã以äžãæäŸããã
ïŒïŒ 骚é«å¢æ®æ§é害ãæ²»çåã¯äºé²ããæ¹æ³ã«ãããŠäœ¿çšããããã®ã¯ã¯ãã³çµæç©ã§ãã£ãŠã
a)
(i)é åçªå·1åã¯é åçªå·16ãå«ããCALRã®ãšã¯ãœã³9å€ç°äœãäŸãã°ãé åçªå·10ã«ç€ºããããCALRã®ãšã¯ãœã³9å€ç°äœã
(ii)é åçªå·10ã«ç€ºããããšã¯ãœã³9å€ç°äœCALRã®ãå ç«åãšããŠæŽ»æ§ã®ããããæçã§ãã£ãŠãé åçªå·10ã®ã¢ããé ž361ã411ã®ãã¡ã®å°ãªããšãäžéšãå«ãæçã
(iii)é åçªå·16è¥ããã¯é åçªå·1ãåã¯ãã®æçãããªããå ç«åãšããŠæŽ»æ§ã®ããããã
(iv)(i)ã(ii)ãåã¯(iii)ã®ããªããããã®æ©èœççžåäœã§ãã£ãŠãé åçªå·10ãšå°ãªããšã70%ã®é ååäžæ§ãå ±æããäžã€/åã¯æ倧ã§3åã®ã¢ããé žãäŸãã°ãæ倧ã§2åã®ã¢ããé žãäŸãã°ãæ倧ã§1åã®ã¢ããé žã眮æãããŠããããšãé€ããé åçªå·16ãé åçªå·1ãè¥ããã¯é åçªå·10ã®ã¢ããé žã®é£ç¶é åãšåäžãªé åãããªããå ç«åãšããŠæŽ»æ§ã®ããªããããã§ããæ©èœççžåäœã
(v)(i)ã(ii)ã(iii)ãåã¯(iv)ã®ããªããããã®ãã¡ã®ãããããå«ãããªããããã
(vi)(i)ã(ii)ã(iii)ã(iv)ãåã¯(v)ã®ããªããããã®ãã¡ã®ãããããã³ãŒãããæ žé ž
ã®ãã¡ã®1ã€ä»¥äžã
åã¯
b)
(vii)é åçªå·6ã«ç€ºãããJAK2V617Få€ç°äœã
(viii)é åçªå·6ã«ç€ºãããJAK2V617Få€ç°äœã®ãå ç«åãšããŠæŽ»æ§ã®ããããæçã§ãã£ãŠãã¢ããé ž617ãå°ãªããšãå«ãæçã
(ix)(vii)åã³(viii)ã®ããªããããã®æ©èœççžåäœã§ãã£ãŠãé åçªå·6ãšå°ãªããšã70%ã®é ååäžæ§ãå ±æããäžã€/åã¯æ倧ã§3åã®ã¢ããé žãäŸãã°ãæ倧ã§2åã®ã¢ããé žãäŸãã°ãæ倧ã§1åã®ã¢ããé žã眮æãããŠããããšãé€ããé åçªå·6ã®ã¢ããé žã®é£ç¶é åãšåäžãªé åãããªããå ç«åãšããŠæŽ»æ§ã®ããªããããã§ãããé åçªå·6ã®ã¢ããé ž617ãå°ãªããšãå«ãæ©èœççžåäœã
(x)(vii)ã(viii)ãåã¯(ix)ã®ããªããããã®ãã¡ã®ãããããå«ãããªããããã
(xi)(vii)ã(viii)ã(ix)ãåã¯(x)ã®ããªããããã®ãã¡ã®ãããããã³ãŒãããæ žé ž
ã®ãã¡ã®1ã€ä»¥äž
ãå«ã¿ã
ã¢ãžã¥ãã³ããããã«å«ã
çµæç©ã
ïŒïŒ ä»»æéžæã§ãã¢ãžã¥ãã³ããããã«å«ããå»è¬ãšããŠäœ¿çšããããã®äžèš1ã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒ åèšå ç«åãšããŠæŽ»æ§ã®ããããæçããé åçªå·10ã®8ã50åã®ã¢ããé žã®ç¯å²ãäŸãã°ã8ã40åã®ã¢ããé žã®ç¯å²ãäŸãã°ã8ã29åã®ã¢ããé žã®ç¯å²ã®é£ç¶é åãåã¯æ倧ã§3åã®ã¢ããé žã眮æãããŠãããã®æ©èœççžåäœãå«ãããåã¯ãããããªããäžèš1åã¯2ã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒ åèšå ç«åãšããŠæŽ»æ§ã®ããããæçããé åçªå·16è¥ããã¯é åçªå·1ã®8ã50åã®ã¢ããé žã®ç¯å²ãäŸãã°ã8ã40åã®ã¢ããé žã®ç¯å²ãäŸãã°ã8ã29åã®ã¢ããé žã®ç¯å²ã®é£ç¶é åãåã¯æ倧ã§3åã®ã¢ããé žã眮æãããŠãããã®æ©èœççžåäœãå«ãããåã¯ãããããªããäžèš1ã3ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒ åèšå ç«åãšããŠæŽ»æ§ã®ããããæçãã
a)é åçªå·2è¥ããã¯é åçªå·3ã®8ã29åã®ã¢ããé žã®ç¯å²ã®é£ç¶é åãåã¯
b)é åçªå·15ã®15ã20åã®ã¢ããé žã®ç¯å²ã®é£ç¶é åãåã¯
c)é åçªå·1ã®25ã36åã®ã¢ããé žã®ç¯å²ã®é£ç¶é åãåã¯
d)é åçªå·17ã®39ã44åã®ã¢ããé žã®ç¯å²ã®é£ç¶é åãåã¯
e)æ倧ã§2åã®ã¢ããé žã眮æãããŠãããã®æ©èœççžåäœ
ãå«ããåã¯ãããããªããäžèš1ã4ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒ åèšå ç«åãšããŠæŽ»æ§ã®ããããæçãã
a)é åçªå·2è¥ããã¯é åçªå·3è¥ããã¯é åçªå·15ã®8ã11åã®ã¢ããé žã®ç¯å²ã®é£ç¶é åãäŸãã°ãé åçªå·2è¥ããã¯é åçªå·3è¥ããã¯é åçªå·15ã®9ã10åã®ã¢ããé žã®é£ç¶é åãåã¯
b)é åçªå·2è¥ããã¯é åçªå·3è¥ããã¯é åçªå·1è¥ããã¯é åçªå·17ã®11ã29åã®ã¢ããé žã®ç¯å²ãäŸãã°ã15ã29åã®ã¢ããé žã®ç¯å²ãäŸãã°ã20ã29åã®ã¢ããé žã®ç¯å²ã®é£ç¶é åãäŸãã°ãé åçªå·2è¥ããã¯é åçªå·3ã®25ã29åã®ã¢ããé žã®é£ç¶é åãåã¯
c)é åçªå·17ã®29ã44åã®ã¢ããé žã®ç¯å²ãäŸãã°ã36ã44åã®ã¢ããé žã®ç¯å²ãäŸãã°ã29ã36åã®ã¢ããé žã®ç¯å²ã®é£ç¶é åãäŸãã°ãé åçªå·17ã®40ã44åã®ã¢ããé žã®é£ç¶é åãåã¯
d)a)ãb)ãåã¯c)ã®æ©èœççžåäœã§ãã£ãŠãæ倧ã§2åã®ã¢ããé žã眮æãããŠããæ©èœççžåäœ
ãå«ããåã¯ãããããªããäžèš1ã5ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒ é åçªå·16åã¯é åçªå·1ãå«ããšã¯ãœã³9å€ç°äœCALRã®çºçŸã«ãã£ãŠç¹åŸŽä»ããããèšåºç¶æ ã«ããåäœã«æäžããããšãé åçªå·16è¥ããã¯é åçªå·1ãå«ããšã¯ãœã³9å€ç°äœCALRãçºçŸãããã现èãåã³/åã¯é åçªå·16è¥ããã¯é åçªå·1ãå«ããšã¯ãœã³9å€ç°äœCALRãçºçŸããæåæ瀺现èã«å¯Ÿããå ç«å¿çãèªçºããããšãå¯èœã§ãããäžèš1ã6ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒ åäœã«ããã现èæ§å ç«å¿çãèªçºããããšãå¯èœã§ãããäžèš1ã7ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒ åèšçŽ°èæ§å ç«å¿çãããšã¯ãœã³9å€ç°äœCALRã«å¯ŸããŠç¹ç°çã§ãããäžèš8ã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ ãšã¯ãœã³9å€ç°äœCALRãç¹ç°çã«èªèãã现èå·å®³æ§T现èã®åœ¢æãèªçºããããšãå¯èœã§ãããäžèš1ã9ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ ãšã¯ãœã³9å€ç°äœCALRãç¹ç°çã«èªèãã现èãå«ããäžèš1ã10ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ åèšå ç«åãšããŠæŽ»æ§ã®ããããæçããé åçªå·6ã®8ã50åã®ã¢ããé žã®ç¯å²ãäŸãã°ã8ã40åã®ã¢ããé žã®ç¯å²ãäŸãã°ã8ã29åã®ã¢ããé žã®ç¯å²ã®é£ç¶é åãåã¯æ倧ã§3åã®ã¢ããé žã眮æãããŠãããã®æ©èœççžåäœãããªããäžèš1ã11ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ åèšå ç«åãšããŠæŽ»æ§ã®ããããæçããé åçªå·7ã®8ã9åã®ã¢ããé žã®ç¯å²ã®é£ç¶é åãåã¯æ倧ã§2åã®ã¢ããé žã眮æãããŠãããã®æ©èœççžåäœãããªããäžèš1ã12ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ åèšå ç«åãšããŠæŽ»æ§ã®ããããæçãã
a)é åçªå·7ã®8ã9åã®ã¢ããé žã®ç¯å²ã®é£ç¶é åã
b)æ倧ã§2åã®ã¢ããé žã眮æãããŠããa)ã®æ©èœççžåäœ
ãå«ããåã¯ãããããªããäžèš1ã13ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ é åçªå·6ã®JAK2V617Fã®çºçŸã«ãã£ãŠç¹åŸŽä»ããããèšåºç¶æ ã«ããåäœã«æäžããããšã现èãäŸãã°ãé åçªå·6ã®JAK2V617Fãåã¯ãããšå°ãªããšã70%ã®é ååäžæ§ãå ±æããæ©èœççžåäœãçºçŸããããã现èåã³/åã¯æåæ瀺现èã«å¯Ÿããå ç«å¿çãèªçºããããšãå¯èœã§ãããäžèš1ã14ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ åäœã«ããã现èæ§å ç«å¿çãèªçºããããšãå¯èœã§ãããäžèš1ã15ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ åèšçŽ°èæ§å ç«å¿çããJAK2V617Fã«å¯ŸããŠç¹ç°çã§ãããäžèš16ã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ JAK2V617Fãç¹ç°çã«èªèãã现èå·å®³æ§T现èã®åœ¢æãèªçºããããšãå¯èœã§ãããäžèš1ã17ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ JAK2V617Fãç¹ç°çã«èªèãã现èãå«ããäžèš1ã18ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ åèšå»è¬ãã骚é«å¢æ®æ§é害ãæ²»çåã¯äºé²ããããã®ãã®ã§ãããäžèš1ã19ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ 骚é«å¢æ®æ§é害ããæ¬æ æ§è¡å°æ¿è¡çãåçºæ§éªšé«ç·ç¶çãçæ§èµ€è¡çå¢å çãåã¯æ¥æ§éªšé«æ§çœè¡ç è¥ããã¯æ ¢æ§éªšé«æ§çœè¡ç ã§ãããäžèš1ã20ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ 以äžã®ç¹åŸŽ:
a)ELISPOTã¢ãã»ã€ã«ãã決å®ããŠãããèšåºç¶æ ã«ããåäœã®ãPBLéå£å ã®INF-γç£ç现èããPBL 104ååœããå°ãªããšã1åã®é »åºŠã§èªçºããããšãå¯èœã§ããããšãåã³/åã¯
b)è «ççµç¹è©Šæäžã®ããšãããŒããããããšåå¿æ§ã§ããCTL(现èå·å®³æ§T现è)ã®ãin situã«ãããæ€åºãå¯èœã§ããããšãåã¯
c)ãšã¯ãœã³9å€ç°äœCALRåã¯JAK2V617Fãç¹ç°çã«èªèããããšãå¯èœã§ããT现èã®å¢æ®ããin vitroã«ãããŠèªå°ããããšãå¯èœã§ããããš
ã®ãã¡ã®å°ãªããšã1ã€ãæããMHCã¯ã©ã¹Iæææ§ãããããå«ããäžèš1ã21ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ MHCã¯ã©ã¹Iååã«ãã£ãŠææãããããããæçãå«ããäžèš1ã22ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ MHCã¯ã©ã¹IIååã«ãã£ãŠææãããããããæçãå«ããäžèš1ã23ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ èšåºç¶æ ã«ããåäœã®PBLéå£å ã®INF-γç£ç现èããPBL 104ååœããå°ãªããšã5åã®é »åºŠã§èªçºããããšãå¯èœã§ããããããæçãå«ããäžèš1ã24ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ é åçªå·16åã¯é åçªå·1ãå«ããšã¯ãœã³9å€ç°äœCALRãçºçŸãããèšåºç¶æ ã«ããåäœã®PBLéå£å ã®INF-γç£ç现èãèªçºããããšãå¯èœã§ããããããæçãå«ããäžèš1ã25ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ é åçªå·6ã®JAK2V617Fãåã¯é åçªå·6ã«å¯ŸããŠå°ãªããšã70%ã®åäžæ§ãæãããã®æ©èœççžåäœãçºçŸãããèšåºç¶æ ã«ããåäœã®ãPBLéå£å ã®INF-γç£ç现èãèªçºããããšãå¯èœã§ããããããæçãå«ããäžèš1ã26ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ 骚é«å¢æ®æ§é害ãããã§ãããäžèš1ã27ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ ããããæçããæ倧ã§50åã®ã¢ããé žæ®åºã奜ãŸããã¯ãæ倧ã§30åã®ã¢ããé žæ®åºããã奜ãŸããã¯ãæ倧ã§20åã®ã¢ããé žæ®åºãäŸãã°ãæ倧ã§9åã®ã¢ããé žæ®åºãããªããäžèš1ã28ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ ããããæçããé åçªå·2ãé åçªå·3ãé åçªå·15ãé åçªå·1ãé åçªå·17ãåã³åè¿°ã®ãã¡ã®ããããã®æ©èœççžåäœã§ãã£ãŠãæ倧ã§3åã®ã¢ããé žã眮æãããŠãããåäžãªé åã®ããªããããã§ããæ©èœççžåäœãããªã矀ããéžæããããäžèš1ã29ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ ããããæçããé åçªå·7åã³ãã®æ©èœççžåäœã§ãã£ãŠãæ倧ã§3åã®ã¢ããé žãäŸãã°ãæ倧ã§2åã®ã¢ããé žãäŸãã°ãæ倧ã§1åã®ã¢ããé žã眮æãããŠãããåäžãªé åã®ããªããããã§ããæ©èœççžåäœãããªã矀ããéžæããããäžèš1ã30ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ ããããæçãé åçªå·7ã§ãããäžèš1ã31ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ åèšããªããããããé åçªå·7ã®ã¢ããé žã®é£ç¶é åã奜ãŸããã¯ãé åçªå·7ãå«ããæ倧ã§100åã®ã¢ããé žã奜ãŸããã¯ãæ倧ã§60åã®ã¢ããé žããã奜ãŸããã¯ãæ倧ã§20åã®ã¢ããé žãäŸãã°ãæ倧ã§9åã®ã¢ããé žã®ããªããããã§ãããäžèš1ã32ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ åèšããªããããããé åçªå·2ãé åçªå·3ãé åçªå·15ãé åçªå·1ãåã¯é åçªå·17ã®ã¢ããé žã®ãã¡ã®å°ãªããšã8ã¢ããé žã®é£ç¶é åãå«ããæ倧ã§100åã®ã¢ããé žã奜ãŸããã¯ãæ倧ã§60åã®ã¢ããé žããã奜ãŸããã¯ãæ倧ã§20åã®ã¢ããé žãäŸãã°ãæ倧ã§9åã®ã¢ããé žã®ããªããããã§ãããäžèš1ã33ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ åèšããªããããããé åçªå·2ãé åçªå·3ãé åçªå·15ãé åçªå·1ãåã¯é åçªå·17ãå«ããæ倧ã§100åã®ã¢ããé žãäŸãã°ãæ倧ã§90åã®ã¢ããé žãäŸãã°ãæ倧ã§80åã®ã¢ããé žãäŸãã°ãæ倧ã§60åã®ã¢ããé žãäŸãã°ãæ倧ã§40åã®ã¢ããé žãäŸãã°ãæ倧ã§30åã®ã¢ããé žãäŸãã°ãæ倧ã§29åã®ã¢ããé žã®ããªããããã§ãããäžèš1ã34ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ ã¯ã¯ãã³ããã¯ã¯ãã³æ¥çš®ãããåäœã«ãããã现èãäŸãã°ãé åçªå·16è¥ããã¯é åçªå·1ãå«ããšã¯ãœã³9å€ç°äœCALRãçºçŸãããã现èãåã³/åã¯é åçªå·16è¥ããã¯é åçªå·1ãå«ããšã¯ãœã³9å€ç°äœCALRã®æåãæ瀺ããæåæ瀺现èã«å¯Ÿãã现èå·å®³å¹æãæããT现èã®ç£çãèªçºãããäžèš1ã35ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ ã¯ã¯ãã³ããã¯ã¯ãã³æ¥çš®ãããåäœã«ããããé åçªå·7ãå«ãå€ç°äœJAK2ãçºçŸãããã现èãåã³/åã¯é åçªå·6ã®å€ç°äœJAK2ã®æåãæ瀺ããæåæ瀺现èã«å¯Ÿãã现èå·å®³å¹æãæããT现èã®ç£çãèªçºãããäžèš1ã36ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ 察象ã«ãããèšåºå¿çãèªçºããããšãå¯èœã§ãããèšåºå¿çããå®å®ãéšåå¥å¹ãåã¯å®å šå¯è§£ã«ããç¹åŸŽä»ãããããäžèš1ã37ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ CALRã§ããšã¯ãœã³9å€ç°äœCALRã§ããªãã¿ã³ãã¯è³ªåã¯ããããæçããéžæãããå ç«åãšããŠæŽ»æ§ã®ã¿ã³ãã¯è³ªåã¯ããããæçãããã«å«ããäžèš1ã38ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ JAK2ã§ãJAK2V617Fã§ããªãã¿ã³ãã¯è³ªåã¯ããããæçããéžæãããå ç«åãšããŠæŽ»æ§ã®ã¿ã³ãã¯è³ªåã¯ããããæçãããã«å«ããäžèš1ã39ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ ã¢ãžã¥ãã³ããã现èDNAããŒã¹ã®ã¢ãžã¥ãã³ããæ²¹/çé¢æŽ»æ§å€ããŒã¹ã®ã¢ãžã¥ãã³ãããŠã€ã«ã¹dsRNAããŒã¹ã®ã¢ãžã¥ãã³ããåã³ã€ãããŸãããªã³ãããªã矀ããéžæããããäžèš1ã40ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ ã¢ãžã¥ãã³ããMontanide ISAã¢ãžã¥ãã³ãã§ãããäžèš1ã41ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ ã¢ãžã¥ãã³ããMontanide ISA 51åã¯Montanide ISA 720ã§ãããäžèš42ã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ ã¢ãžã¥ãã³ããMontanide ISA 51ã§ãããäžèš43ã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ ã¢ãžã¥ãã³ããGM-CSFã§ãããäžèš1ã41ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ å ç«åãšããŠæŽ»æ§ã®ããããæçãåã¯åèšå ç«åãšããŠæŽ»æ§ã®ããããæçãã³ãŒãããæ žé žãå«ãæåæ瀺现èãå«ããäžèš1ã45ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ æåæ瀺现èãæš¹ç¶çŽ°èã§ãããäžèš45ã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ æ žé žããäžèš1ã47ã®ããããã«èšèŒã®ãããããã³ãŒããããäžèš2åã¯äžèš3ã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ æ žé žããã¯ã¿ãŒå ã«å«ãŸãããäžèš1ã48ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ ãã¯ã¿ãŒãããŠã€ã«ã¹ãã¯ã¿ãŒåã³çŽ°èãã¯ã¿ãŒãããªã矀ããéžæããããäžèš48ã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ ãã¯ã¿ãŒããT现èåºæ¿æ§ããªãããããã³ãŒãããæ žé žãããã«å«ããäžèš48åã¯49ã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ é åçªå·16è¥ããã¯é åçªå·1ãå«ããšã¯ãœã³9å€ç°äœCALRåã³/åã¯é åçªå·6ã®å€ç°äœJAK2V617FãçºçŸããã骚é«å¢æ®æ§é害ãæ²»çããããã®ãã®ã§ãããäžèš1ã51ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ äžèš1ã51ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ãåã³ç¬¬2ã®æå¹æåãå«ããããã
ïŒïŒïŒ 第2ã®æå¹æåãå ç«åºæ¿çµæç©ã§ãããäžèš53ã«èšèŒã®ãããã
ïŒïŒïŒ å ç«åºæ¿çµæç©ãIFN-γãå«ããäžèš54ã«èšèŒã®ãããã
ïŒïŒïŒ ãããªãå ç«åºæ¿çµæç©ãã1皮以äžã®ã€ã³ã¿ãŒãã€ãã³ãå«ããäžèš54åã¯55ã«èšèŒã®ãããã
ïŒïŒïŒ ã€ã³ã¿ãŒãã€ãã³ããIL-2åã³/åã¯IL-21ããéžæããããäžèš53ã56ã®ããããã«èšèŒã®ãããã
ïŒïŒïŒ 第2ã®æå¹æåãæããå€ã§ãããäžèš53ã56ã®ããããã«èšèŒã®ãããã
ïŒïŒïŒ æããå€ãååŠçæ³å€ã§ãããäžèš58ã«èšèŒã®ãããã
ïŒïŒïŒ ååŠçæ³å€ããã¢ã¯ããããã¢ã¶ã·ããžã³ãã¢ã¶ããªããªã³ããã¬ãªãã€ã·ã³ãã«ã«ããã©ãã³ãã«ãã·ã¿ãã³ãã·ã¹ãã©ãã³ãã¯ãã©ã ãã·ã«ãã·ã¯ããã¹ãã¡ãããã·ã¿ã©ãã³ãããŠãã«ãã·ã³ããã»ã¿ãã»ã«ãããã·ãã«ãªãžã³ããããœã«ãã·ã³ããšãã«ãã·ã³ããšããã·ãããã«ãã©ãã³ããã«ãªããŠã©ã·ã«ãã²ã ã·ã¿ãã³ãããããã·ãŠã¬ã¢ãã€ãã«ãã·ã³ãã€ãªããã«ã³ãã¬ããªãããããã€ã³ããªã³ãã¡ã¯ãã¬ã¿ãã³ãã¡ã«ãã¡ã©ã³ãã¡ã«ã«ããããªã³ãã¡ããã¬ããµãŒããããããµã³ããã³ããªããµãªãã©ãã³ããã¯ãªã¿ãã»ã«ããã¡ãã¬ãã»ããã¬ããªããããã¢ãŸãããããããã·ããããªã°ã¢ãã³ããã«ã«ãã·ã³ããã³ãã©ã¹ãã³ããã³ã¯ãªã¹ãã³ããã³ãã·ã³ãåã³ããã¬ã«ãã³ããéžæããããäžèš59ã«èšèŒã®ãããã
ïŒïŒïŒ 第2ã®æå¹æåãæçç©è³ªã§ãããäžèš53ã60ã®ããããã«èšèŒã®ãããã
ïŒïŒïŒ æçç©è³ªããã¢ã¢ãã·ãªã³ãããã·ãªã³ãã¢ã·ã¯ããã«ãåã³/åã¯ããã©ãã³ããéžæããããäžèš61ã«èšèŒã®ã¯ã¯ãã³çµæç©ãå«ããããã
ïŒïŒïŒ æäŸãããçµæç©ããåæã«ãåã¯é次çã«æäžããããäžèš53ã62ã®ããããã«èšèŒã®ãããã
ïŒïŒïŒ äžèš1ã52ã®ããããã«èšèŒã®ããããæçãåã³ã¯ã©ã¹Iã®HLAååè¥ããã¯ã¯ã©ã¹IIã®HLAååãåã¯ãã®ãããªååã®æçã®è€åäœã
ïŒïŒïŒ åéäœã§ãããäžèš64ã«èšèŒã®è€åäœã
ïŒïŒïŒ å€éäœã§ãããäžèš64ã«èšèŒã®è€åäœã
ïŒïŒïŒ ããèšåºç¶æ ã«ããåäœã«ãããŠããšã¯ãœã³9å€ç°äœCALRã«å¯ŸããŠåå¿æ§ã®T现èãåã¯JAK2V617Fã«å¯ŸããŠåå¿æ§ã®T现èã®ååšãæ€åºããæ¹æ³ã§ãã£ãŠãè «ççµç¹åã¯è¡æ¶²è©Šæããäžèš64ãã66ã®ããããã«èšèŒã®è€åäœãšæ¥è§Šãããã¹ããããåã³è€åäœã®ãçµç¹åã¯è¡æ¶²çŽ°èãšã®çµåãæ€åºããã¹ãããããå«ãæ¹æ³ã
ïŒïŒïŒ äžèš1ã52ã103ã104ãåã¯107ã108ã®ããããã«èšèŒã®ããããæçã«ç¹ç°çã«çµåããããšãå¯èœã§ããååã
ïŒïŒïŒ æäœåã¯ãã®æçã§ãããäžèš68ã«èšèŒã®ååã
ïŒïŒïŒ T现èå容äœã§ãããäžèš68åã¯69ã«èšèŒã®ååã
ïŒïŒïŒ äžèš68ã70ã®ããããã«èšèŒã®ååã®çµåãé®æããããšãå¯èœã§ããååã
ïŒïŒïŒ ãšã¯ãœã³9å€ç°äœCALRã®çºçŸåã³/åã¯JAK2V617Fã®çºçŸã«ãã£ãŠç¹åŸŽä»ããããèšåºç¶æ ãæ²»çåã¯äºé²ããæ¹æ³ã§ãã£ãŠãåèšèšåºç¶æ ã«ããåäœã«ãæå¹éã®ãäžèš1ã52ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ãäžèš68ã71ã®ããããã«èšèŒã®ååãäžèš97ã102ã®ããããã«èšèŒã®çµæç©ãåã¯äžèš103ã104è¥ããã¯107ã108ã®ããããã«èšèŒã®ãããããæäžããã¹ããããå«ãæ¹æ³ã
ïŒïŒïŒ æ²»çåã¯äºé²ãããèšåºç¶æ ãããšã¯ãœã³9å€ç°äœCALRåã³/åã¯JAK2V617FãçºçŸãããããçŸæ£ã§ãããäžèš72ã«èšèŒã®æ¹æ³ã
ïŒïŒïŒ ãããªãããæ²»çãšçµã¿åãããããäžèš72åã¯73ã«èšèŒã®æ¹æ³ã
ïŒïŒïŒ ãããªãæ²»çããååŠçæ³ãæŸå°ç·æ²»çãå ç«åºæ¿ç©è³ªã«ããæ²»çãéºäŒåæ²»çãæäœã«ããæ²»çãåã³æš¹ç¶çŽ°èã䜿çšããæ²»çãããªã矀ããéžæããããäžèš74ã«èšèŒã®æ¹æ³ã
ïŒïŒïŒ æ²»çåã¯äºé²ãããèšåºç¶æ ããæåæ瀺现èå ã®ãšã¯ãœã³9å€ç°äœCALRã®çºçŸåã³/åã¯JAK2V617Fã®çºçŸãåŒãèµ·ããé害ã§ãããäžèš72ã75ã®ããããã«èšèŒã®æ¹æ³ã
ïŒïŒïŒ åèšé害ã«å¯Ÿãããããªãæ²»çãšçµã¿åãããããäžèš76ã«èšèŒã®æ¹æ³ã
ïŒïŒïŒ ãããªãæ²»çããååŠçæ³ãå ç«åºæ¿ç©è³ªã«ããæ²»çãéºäŒåæ²»çãæäœã«ããæ²»çãåã³æš¹ç¶çŽ°èã䜿çšããæ²»çãããªã矀ããéžæããããäžèš77ã«èšèŒã®æ¹æ³ã
ïŒïŒïŒ ãšã¯ãœã³9å€ç°äœCALRåã¯JAK2V617Fã®å ç«åãšããŠæŽ»æ§ã®ããããæçããåäœåœãã50ÎŒgã500ÎŒgã®ç¯å²ãäŸãã°ã80ÎŒgã300ÎŒgã®ç¯å²ãäŸãã°ã100ÎŒgã250ÎŒgã®ç¯å²ã®çšéã§æäžãããåäœãã奜ãŸããã¯ããã§ãããäžèš72ã78ã®ããããã«èšèŒã®æ¹æ³ã
ïŒïŒïŒ èšåºç¶æ ãæ²»çåã¯äºé²ããããã®å»è¬ã®è£œé ã«ããããäžèš1ã72ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ãäžèš74ã63ã®ããããã«èšèŒã®ããããäžèš68ã70ã®ããããã«èšèŒã®ååãåã¯äžèš89ã96ã®ããããã«èšèŒã®ããããæçã®äœ¿çšã
ïŒïŒïŒ æ²»çåã¯äºé²ãããçŸæ£ãããšã¯ãœã³9å€ç°äœCALRåã³/åã¯JAK2V617FãçºçŸãããããçŸæ£ã§ãããäžèš80ã«èšèŒã®äœ¿çšã
ïŒïŒïŒ ãããªãããæ²»çãšçµã¿åãããããäžèš80åã¯81ã«èšèŒã®äœ¿çšã
ïŒïŒïŒ ãããªãæ²»çããååŠçæ³ãæŸå°ç·æ²»çãå ç«åºæ¿ç©è³ªã«ããæ²»çãéºäŒåæ²»çãæäœã«ããæ²»çãåã³æš¹ç¶çŽ°èã䜿çšããæ²»çãããªã矀ããéžæããããäžèš82ã«èšèŒã®äœ¿çšã
ïŒïŒïŒ æ²»çåã¯äºé²ãããèšåºç¶æ ããæåæ瀺现èå ã®ãšã¯ãœã³9å€ç°äœCALRã®çºçŸåã³/åã¯JAK2V617Fã®çºçŸãåŒãèµ·ããé害ã§ãããäžèš83ã«èšèŒã®äœ¿çšã
ïŒïŒïŒ åèšææã«å¯Ÿãããããªãæ²»çãšçµã¿åãããããäžèš84ã«èšèŒã®äœ¿çšã
ïŒïŒïŒ ãããªãæ²»çããååŠçæ³ãå ç«åºæ¿ç©è³ªã«ããæ²»çãéºäŒåæ²»çãæäœã«ããæ²»çãåã³æš¹ç¶çŽ°èã䜿çšããæ²»çãããªã矀ããéžæããããäžèš85ã«èšèŒã®äœ¿çšã
ïŒïŒïŒ å ç«åãã¢ãã¿ãªã³ã°ããæ¹æ³ã§ãã£ãŠã
a)åäœã«ç±æ¥ããè¡æ¶²è©Šæãçšæããã¹ãããã
b)(i)é åçªå·16åã¯é åçªå·1ãå«ãCALRã®ãšã¯ãœã³9å€ç°äœãäŸãã°ãé åçªå·10ã«ç€ºããããCALRã®ãšã¯ãœã³9å€ç°äœãåã¯
(ii)é åçªå·10ã«ç€ºããããšã¯ãœã³9å€ç°äœCALRã®ãå ç«åãšããŠæŽ»æ§ã®ããããæçã§ãã£ãŠãé åçªå·10ã®ã¢ããé ž361ã411ã®ãã¡ã®å°ãªããšãäžéšãå«ãæçãåã¯
(iii)é åçªå·1ãé åçªå·2ãé åçªå·3ãé åçªå·15ãè¥ããã¯é åçªå·17ãåã¯ãã®æçãããªããå ç«åãšããŠæŽ»æ§ã®ãããããåã¯
(iv)é åçªå·6ã«ç€ºãããJAK2V617Få€ç°äœãåã¯
(v)é åçªå·6ã«ç€ºãããJAK2V617Få€ç°äœã®ãå ç«åãšããŠæŽ»æ§ã®ããããæçã§ãã£ãŠãé åçªå·6ã®ã¢ããé ž617ãå°ãªããšãå«ãæçãåã¯
(vi)åè¿°ã®ãã¡ã®ããããã®æ©èœççžåäœ
ãçšæããã¹ãããã
c)åèšè¡æ¶²è©Šæããã¿ã³ãã¯è³ªåã¯ããããã«ç¹ç°çã«çµåãããæäœãåã¯T现èå容äœãå«ãT现èãå«ããã©ããã決å®ããã¹ããã
ãå«ã¿ã
ããã«ãããåèšã¿ã³ãã¯è³ªåã¯ããããã«å¯Ÿããå ç«å¿çããåèšåäœã«ãããŠæ¹èµ·ããããã©ããã決å®ãã
æ¹æ³ã
ïŒïŒïŒ ããããæçããäžèš1ã52ã®ããããã«èšèŒã®ããããæçã§ãããäžèš87ã«èšèŒã®æ¹æ³ã
ïŒïŒïŒ å€ç°äœCALRã®çºçŸãšé¢é£ããèšåºç¶æ ãäŸãã°ã骚é«å¢æ®æ§é害ã®æ²»çåã¯äºé²ã«ãããŠäœ¿çšããããã®ãé åçªå·16è¥ããã¯é åçªå·1ã®é£ç¶é åã®ãã¡ã®å°ãªããšãäžéšãå«ããå ç«åãšããŠæŽ»æ§ã®ãšã¯ãœã³9å€ç°äœCALRã®ããããæçãåã¯ãã®æ©èœççžåäœã§ãã£ãŠãæ倧ã§3åã®ã¢ããé žã眮æãããŠããããšãé€ããåäžãªé åã®ããªããããã§ããæ©èœççžåäœãåã¯åèšããããæçãã³ãŒãããæ žé žã
ïŒïŒïŒ äžèš1ã52ã®ããããã«èšèŒã®ããããæçã§ãããäžèš89ã«èšèŒã®ããããæçã
ïŒïŒïŒ ããã®æ²»çåã¯äºé²ã«ãããŠäœ¿çšããããã®ãäžèš89åã¯90ã«èšèŒã®ããããæçã
ïŒïŒïŒ ãšã¯ãœã³9å€ç°äœCALRã®çºçŸãšé¢é£ããèšåºç¶æ ãäŸãã°ã骚é«å¢æ®æ§é害ã®æ²»çåã¯äºé²ã«ãããŠäœ¿çšããããã®ãé åçªå·2ãé åçªå·3ãé åçªå·15ãé åçªå·1ãè¥ããã¯é åçªå·17ãå«ããåã¯ãããããªããäžèš89ã91ã®ããããã«èšèŒã®ããããæçãåã¯ãã®æ©èœççžåäœã§ãã£ãŠãæ倧ã§3åã®ã¢ããé žã眮æãããŠããããšãé€ããåäžãªé åã®ããªããããã§ããæ©èœççžåäœãåã¯åèšCALRã®ããããæçãã³ãŒãããæ žé žã
ïŒïŒïŒ å€ç°äœJAK2V617Fã®çºçŸãšé¢é£ããèšåºç¶æ ãäŸãã°ã骚é«å¢æ®æ§é害ã®æ²»çåã¯äºé²ã«ãããŠäœ¿çšããããã®ãé åçªå·7ã®é£ç¶é åã®ãã¡ã®å°ãªããšãäžéšãå«ããå ç«åãšããŠæŽ»æ§ã®JAK2V617Fã®ããããæçãåã¯ãã®æ©èœççžåäœã§ãã£ãŠãæ倧ã§3åã®ã¢ããé žã眮æãããŠããããšãé€ããåäžãªé åã®ããªããããã§ããæ©èœççžåäœãåã¯åèšJAK2V617Fã®ããããæçãã³ãŒãããæ žé žã
ïŒïŒïŒ äžèš1ã52ã®ããããã«èšèŒã®ããããæçã§ãããäžèš93ã«èšèŒã®ããããæçã
ïŒïŒïŒ ããã®æ²»çåã¯äºé²ã«ãããŠäœ¿çšããããã®ãäžèš93åã¯94ã«èšèŒã®ããããæçã
ïŒïŒïŒ JAK2V617Fã®çºçŸãšé¢é£ããèšåºç¶æ ãäŸãã°ã骚é«å¢æ®æ§é害ã®æ²»çåã¯äºé²ã«ãããŠäœ¿çšããããã®ãé åçªå·7ãå«ããè¥ããã¯ãããããªããäžèš93ã95ã®ããããã«èšèŒã®ããããæçãåã¯ãã®æ©èœççžåäœã§ãã£ãŠãæ倧ã§3åã®ã¢ããé žã眮æãããŠããããšãé€ããåäžãªé åã®ããªããããã§ããæ©èœççžåäœãåã¯åèšJAK2ã®ããããæçãã³ãŒãããæ žé žã
ïŒïŒïŒ ãšã¯ãœã³9å€ç°äœCALRãç¹ç°çã«èªèãã现èãå«ãçµæç©ã§ãã£ãŠã奜ãŸããã¯ããšã¯ãœã³9å€ç°äœCALRããæ倧ã§3åã®ã¢ããé žã眮æãããé åçªå·16ã®é£ç¶é åãå«ããçµæç©ã
ïŒïŒïŒ 现èãã现èå·å®³æ§T现èã§ãããäžèš97ã«èšèŒã®çµæç©ã
ïŒïŒïŒ 现èããäžèšã®ããããã«èšèŒã®ããããè¥ããã¯ããããæçãåã¯äžèš103ã104ã«èšèŒã®ããããè¥ããã¯ããããæçããT现èãå«ã现èéå£ãšæ¥è§Šãããããšã«ããåŸããããäžèš97åã¯98ã«èšèŒã®çµæç©ã
ïŒïŒïŒïŒ JAK2V617Fãç¹ç°çã«èªèãã现èãå«ãçµæç©ã§ãã£ãŠã奜ãŸããã¯ãJAK2V617Fããæ倧ã§3åã®ã¢ããé žã眮æãããé åçªå·6ã®é£ç¶é åãå«ããçµæç©ã
ïŒïŒïŒïŒ 现èãã现èå·å®³æ§T现èã§ãããäžèš100ã«èšèŒã®çµæç©ã
ïŒïŒïŒïŒ 现èããäžèš107åã¯108ã«èšèŒã®ããããåã¯ããããæçããT现èãå«ã现èéå£ãšæ¥è§Šãããããšã«ããåŸããããäžèš100åã¯101ã«èšèŒã®çµæç©ã
ïŒïŒïŒïŒ CALRã®é å(é åçªå·9)ãåã¯é åçªå·1ã®é åãå«ãCALRã®ãšã¯ãœã³9å€ç°äœã®é åã®ãã¡ã®50ãŸã§ã®é£ç¶ã¢ããé žãå«ãããåã¯ãããããªãããããã§ãã£ãŠãåèšå€ç°äœããä»»æéžæã§ãé åçªå·10ã®é åãæããåèšé£ç¶ã¢ããé žããé åçªå·1ã2ã3ã15ã16ãåã¯17ã®ãã¡ã®ãããã1ã€ã®é åãå«ã¿ããã奜ãŸããã¯ãåèšé£ç¶ã¢ããé žããé åçªå·1ãé åçªå·2ãé åçªå·3ãåã¯é åçªå·17ãå«ã¿ãä»»æéžæã§ãæ倧ã§1ã10åã®éã®é£ç¶ã¢ããé žãã眮æãäŸãã°ãä¿åç眮æã«ãã眮ãæããããŠãããããããã
ïŒïŒïŒïŒ å ç«åãšããŠæŽ»æ§ã§ãããäžèš103ã«èšèŒã®ããããã
ïŒïŒïŒïŒ äžèš103åã¯104ã«èšèŒã®ããããã䞊ã³ã«ä»»æéžæã§ä¿åå€åã³/åã¯ã¢ãžã¥ãã³ããå«ãå»è¬çµæç©ã
ïŒïŒïŒïŒ ãããå¿ èŠãšããåäœãæ²»çããæ¹æ³ã§ãã£ãŠãäžèš103åã¯104ã«èšèŒã®ãããããåèšåäœã«æäžããã¹ããããå«ãæ¹æ³ã
ïŒïŒïŒïŒ JAK2ã®é å(é åçªå·5)ãåã¯é åçªå·6ã®é åãå«ãJAK2V617Fã®é åã®ãã¡ã®50åãŸã§ã®é£ç¶ã¢ããé žãå«ãããåã¯ãããããªãããããã§ãã£ãŠãåèšé£ç¶ã¢ããé žããé åçªå·7ã®é åãå«ã¿ãä»»æéžæã§ãæ倧ã§1ã10åã®éã®é£ç¶ã¢ããé žãã眮æãäŸãã°ãä¿åç眮æã«ãã眮ãæããããŠãããããããã
ïŒïŒïŒïŒ å ç«åãšããŠæŽ»æ§ã§ãããäžèš107ã«èšèŒã®ããããã
ïŒïŒïŒïŒ äžèš107åã¯108ã«èšèŒã®ããããã䞊ã³ã«ä»»æéžæã§ä¿åå€åã³/åã¯ã¢ãžã¥ãã³ããå«ãå»è¬çµæç©ã
ïŒïŒïŒïŒ ãããå¿ èŠãšããåäœãæ²»çããæ¹æ³ã§ãã£ãŠãäžèš107åã¯108ã«èšèŒã®ãããããåèšåäœã«æäžããã¹ããããå«ãæ¹æ³ã
å®çŸ©ïŒœ
ã¢ãžã¥ãã³ã:æäžãããå ç«åãšããŠæŽ»æ§ã®ãããã/æå/æ žé žæ§ç¯ç©ãšã®æ··åå€ããåèšãããã/æåã«å¯Ÿããå ç«å¿çãå¢å ããããåã¯ããã§ãªãå Žåã¯æ¹å€ããä»»æã®ç©è³ªã
ïŒïŒ 骚é«å¢æ®æ§é害ãæ²»çåã¯äºé²ããæ¹æ³ã«ãããŠäœ¿çšããããã®ã¯ã¯ãã³çµæç©ã§ãã£ãŠã
a)
(i)é åçªå·1åã¯é åçªå·16ãå«ããCALRã®ãšã¯ãœã³9å€ç°äœãäŸãã°ãé åçªå·10ã«ç€ºããããCALRã®ãšã¯ãœã³9å€ç°äœã
(ii)é åçªå·10ã«ç€ºããããšã¯ãœã³9å€ç°äœCALRã®ãå ç«åãšããŠæŽ»æ§ã®ããããæçã§ãã£ãŠãé åçªå·10ã®ã¢ããé ž361ã411ã®ãã¡ã®å°ãªããšãäžéšãå«ãæçã
(iii)é åçªå·16è¥ããã¯é åçªå·1ãåã¯ãã®æçãããªããå ç«åãšããŠæŽ»æ§ã®ããããã
(iv)(i)ã(ii)ãåã¯(iii)ã®ããªããããã®æ©èœççžåäœã§ãã£ãŠãé åçªå·10ãšå°ãªããšã70%ã®é ååäžæ§ãå ±æããäžã€/åã¯æ倧ã§3åã®ã¢ããé žãäŸãã°ãæ倧ã§2åã®ã¢ããé žãäŸãã°ãæ倧ã§1åã®ã¢ããé žã眮æãããŠããããšãé€ããé åçªå·16ãé åçªå·1ãè¥ããã¯é åçªå·10ã®ã¢ããé žã®é£ç¶é åãšåäžãªé åãããªããå ç«åãšããŠæŽ»æ§ã®ããªããããã§ããæ©èœççžåäœã
(v)(i)ã(ii)ã(iii)ãåã¯(iv)ã®ããªããããã®ãã¡ã®ãããããå«ãããªããããã
(vi)(i)ã(ii)ã(iii)ã(iv)ãåã¯(v)ã®ããªããããã®ãã¡ã®ãããããã³ãŒãããæ žé ž
ã®ãã¡ã®1ã€ä»¥äžã
åã¯
b)
(vii)é åçªå·6ã«ç€ºãããJAK2V617Få€ç°äœã
(viii)é åçªå·6ã«ç€ºãããJAK2V617Få€ç°äœã®ãå ç«åãšããŠæŽ»æ§ã®ããããæçã§ãã£ãŠãã¢ããé ž617ãå°ãªããšãå«ãæçã
(ix)(vii)åã³(viii)ã®ããªããããã®æ©èœççžåäœã§ãã£ãŠãé åçªå·6ãšå°ãªããšã70%ã®é ååäžæ§ãå ±æããäžã€/åã¯æ倧ã§3åã®ã¢ããé žãäŸãã°ãæ倧ã§2åã®ã¢ããé žãäŸãã°ãæ倧ã§1åã®ã¢ããé žã眮æãããŠããããšãé€ããé åçªå·6ã®ã¢ããé žã®é£ç¶é åãšåäžãªé åãããªããå ç«åãšããŠæŽ»æ§ã®ããªããããã§ãããé åçªå·6ã®ã¢ããé ž617ãå°ãªããšãå«ãæ©èœççžåäœã
(x)(vii)ã(viii)ãåã¯(ix)ã®ããªããããã®ãã¡ã®ãããããå«ãããªããããã
(xi)(vii)ã(viii)ã(ix)ãåã¯(x)ã®ããªããããã®ãã¡ã®ãããããã³ãŒãããæ žé ž
ã®ãã¡ã®1ã€ä»¥äž
ãå«ã¿ã
ã¢ãžã¥ãã³ããããã«å«ã
çµæç©ã
ïŒïŒ ä»»æéžæã§ãã¢ãžã¥ãã³ããããã«å«ããå»è¬ãšããŠäœ¿çšããããã®äžèš1ã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒ åèšå ç«åãšããŠæŽ»æ§ã®ããããæçããé åçªå·10ã®8ã50åã®ã¢ããé žã®ç¯å²ãäŸãã°ã8ã40åã®ã¢ããé žã®ç¯å²ãäŸãã°ã8ã29åã®ã¢ããé žã®ç¯å²ã®é£ç¶é åãåã¯æ倧ã§3åã®ã¢ããé žã眮æãããŠãããã®æ©èœççžåäœãå«ãããåã¯ãããããªããäžèš1åã¯2ã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒ åèšå ç«åãšããŠæŽ»æ§ã®ããããæçããé åçªå·16è¥ããã¯é åçªå·1ã®8ã50åã®ã¢ããé žã®ç¯å²ãäŸãã°ã8ã40åã®ã¢ããé žã®ç¯å²ãäŸãã°ã8ã29åã®ã¢ããé žã®ç¯å²ã®é£ç¶é åãåã¯æ倧ã§3åã®ã¢ããé žã眮æãããŠãããã®æ©èœççžåäœãå«ãããåã¯ãããããªããäžèš1ã3ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒ åèšå ç«åãšããŠæŽ»æ§ã®ããããæçãã
a)é åçªå·2è¥ããã¯é åçªå·3ã®8ã29åã®ã¢ããé žã®ç¯å²ã®é£ç¶é åãåã¯
b)é åçªå·15ã®15ã20åã®ã¢ããé žã®ç¯å²ã®é£ç¶é åãåã¯
c)é åçªå·1ã®25ã36åã®ã¢ããé žã®ç¯å²ã®é£ç¶é åãåã¯
d)é åçªå·17ã®39ã44åã®ã¢ããé žã®ç¯å²ã®é£ç¶é åãåã¯
e)æ倧ã§2åã®ã¢ããé žã眮æãããŠãããã®æ©èœççžåäœ
ãå«ããåã¯ãããããªããäžèš1ã4ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒ åèšå ç«åãšããŠæŽ»æ§ã®ããããæçãã
a)é åçªå·2è¥ããã¯é åçªå·3è¥ããã¯é åçªå·15ã®8ã11åã®ã¢ããé žã®ç¯å²ã®é£ç¶é åãäŸãã°ãé åçªå·2è¥ããã¯é åçªå·3è¥ããã¯é åçªå·15ã®9ã10åã®ã¢ããé žã®é£ç¶é åãåã¯
b)é åçªå·2è¥ããã¯é åçªå·3è¥ããã¯é åçªå·1è¥ããã¯é åçªå·17ã®11ã29åã®ã¢ããé žã®ç¯å²ãäŸãã°ã15ã29åã®ã¢ããé žã®ç¯å²ãäŸãã°ã20ã29åã®ã¢ããé žã®ç¯å²ã®é£ç¶é åãäŸãã°ãé åçªå·2è¥ããã¯é åçªå·3ã®25ã29åã®ã¢ããé žã®é£ç¶é åãåã¯
c)é åçªå·17ã®29ã44åã®ã¢ããé žã®ç¯å²ãäŸãã°ã36ã44åã®ã¢ããé žã®ç¯å²ãäŸãã°ã29ã36åã®ã¢ããé žã®ç¯å²ã®é£ç¶é åãäŸãã°ãé åçªå·17ã®40ã44åã®ã¢ããé žã®é£ç¶é åãåã¯
d)a)ãb)ãåã¯c)ã®æ©èœççžåäœã§ãã£ãŠãæ倧ã§2åã®ã¢ããé žã眮æãããŠããæ©èœççžåäœ
ãå«ããåã¯ãããããªããäžèš1ã5ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒ é åçªå·16åã¯é åçªå·1ãå«ããšã¯ãœã³9å€ç°äœCALRã®çºçŸã«ãã£ãŠç¹åŸŽä»ããããèšåºç¶æ ã«ããåäœã«æäžããããšãé åçªå·16è¥ããã¯é åçªå·1ãå«ããšã¯ãœã³9å€ç°äœCALRãçºçŸãããã现èãåã³/åã¯é åçªå·16è¥ããã¯é åçªå·1ãå«ããšã¯ãœã³9å€ç°äœCALRãçºçŸããæåæ瀺现èã«å¯Ÿããå ç«å¿çãèªçºããããšãå¯èœã§ãããäžèš1ã6ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒ åäœã«ããã现èæ§å ç«å¿çãèªçºããããšãå¯èœã§ãããäžèš1ã7ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒ åèšçŽ°èæ§å ç«å¿çãããšã¯ãœã³9å€ç°äœCALRã«å¯ŸããŠç¹ç°çã§ãããäžèš8ã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ ãšã¯ãœã³9å€ç°äœCALRãç¹ç°çã«èªèãã现èå·å®³æ§T现èã®åœ¢æãèªçºããããšãå¯èœã§ãããäžèš1ã9ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ ãšã¯ãœã³9å€ç°äœCALRãç¹ç°çã«èªèãã现èãå«ããäžèš1ã10ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ åèšå ç«åãšããŠæŽ»æ§ã®ããããæçããé åçªå·6ã®8ã50åã®ã¢ããé žã®ç¯å²ãäŸãã°ã8ã40åã®ã¢ããé žã®ç¯å²ãäŸãã°ã8ã29åã®ã¢ããé žã®ç¯å²ã®é£ç¶é åãåã¯æ倧ã§3åã®ã¢ããé žã眮æãããŠãããã®æ©èœççžåäœãããªããäžèš1ã11ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ åèšå ç«åãšããŠæŽ»æ§ã®ããããæçããé åçªå·7ã®8ã9åã®ã¢ããé žã®ç¯å²ã®é£ç¶é åãåã¯æ倧ã§2åã®ã¢ããé žã眮æãããŠãããã®æ©èœççžåäœãããªããäžèš1ã12ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ åèšå ç«åãšããŠæŽ»æ§ã®ããããæçãã
a)é åçªå·7ã®8ã9åã®ã¢ããé žã®ç¯å²ã®é£ç¶é åã
b)æ倧ã§2åã®ã¢ããé žã眮æãããŠããa)ã®æ©èœççžåäœ
ãå«ããåã¯ãããããªããäžèš1ã13ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ é åçªå·6ã®JAK2V617Fã®çºçŸã«ãã£ãŠç¹åŸŽä»ããããèšåºç¶æ ã«ããåäœã«æäžããããšã现èãäŸãã°ãé åçªå·6ã®JAK2V617Fãåã¯ãããšå°ãªããšã70%ã®é ååäžæ§ãå ±æããæ©èœççžåäœãçºçŸããããã现èåã³/åã¯æåæ瀺现èã«å¯Ÿããå ç«å¿çãèªçºããããšãå¯èœã§ãããäžèš1ã14ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ åäœã«ããã现èæ§å ç«å¿çãèªçºããããšãå¯èœã§ãããäžèš1ã15ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ åèšçŽ°èæ§å ç«å¿çããJAK2V617Fã«å¯ŸããŠç¹ç°çã§ãããäžèš16ã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ JAK2V617Fãç¹ç°çã«èªèãã现èå·å®³æ§T现èã®åœ¢æãèªçºããããšãå¯èœã§ãããäžèš1ã17ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ JAK2V617Fãç¹ç°çã«èªèãã现èãå«ããäžèš1ã18ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ åèšå»è¬ãã骚é«å¢æ®æ§é害ãæ²»çåã¯äºé²ããããã®ãã®ã§ãããäžèš1ã19ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ 骚é«å¢æ®æ§é害ããæ¬æ æ§è¡å°æ¿è¡çãåçºæ§éªšé«ç·ç¶çãçæ§èµ€è¡çå¢å çãåã¯æ¥æ§éªšé«æ§çœè¡ç è¥ããã¯æ ¢æ§éªšé«æ§çœè¡ç ã§ãããäžèš1ã20ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ 以äžã®ç¹åŸŽ:
a)ELISPOTã¢ãã»ã€ã«ãã決å®ããŠãããèšåºç¶æ ã«ããåäœã®ãPBLéå£å ã®INF-γç£ç现èããPBL 104ååœããå°ãªããšã1åã®é »åºŠã§èªçºããããšãå¯èœã§ããããšãåã³/åã¯
b)è «ççµç¹è©Šæäžã®ããšãããŒããããããšåå¿æ§ã§ããCTL(现èå·å®³æ§T现è)ã®ãin situã«ãããæ€åºãå¯èœã§ããããšãåã¯
c)ãšã¯ãœã³9å€ç°äœCALRåã¯JAK2V617Fãç¹ç°çã«èªèããããšãå¯èœã§ããT现èã®å¢æ®ããin vitroã«ãããŠèªå°ããããšãå¯èœã§ããããš
ã®ãã¡ã®å°ãªããšã1ã€ãæããMHCã¯ã©ã¹Iæææ§ãããããå«ããäžèš1ã21ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ MHCã¯ã©ã¹Iååã«ãã£ãŠææãããããããæçãå«ããäžèš1ã22ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ MHCã¯ã©ã¹IIååã«ãã£ãŠææãããããããæçãå«ããäžèš1ã23ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ èšåºç¶æ ã«ããåäœã®PBLéå£å ã®INF-γç£ç现èããPBL 104ååœããå°ãªããšã5åã®é »åºŠã§èªçºããããšãå¯èœã§ããããããæçãå«ããäžèš1ã24ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ é åçªå·16åã¯é åçªå·1ãå«ããšã¯ãœã³9å€ç°äœCALRãçºçŸãããèšåºç¶æ ã«ããåäœã®PBLéå£å ã®INF-γç£ç现èãèªçºããããšãå¯èœã§ããããããæçãå«ããäžèš1ã25ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ é åçªå·6ã®JAK2V617Fãåã¯é åçªå·6ã«å¯ŸããŠå°ãªããšã70%ã®åäžæ§ãæãããã®æ©èœççžåäœãçºçŸãããèšåºç¶æ ã«ããåäœã®ãPBLéå£å ã®INF-γç£ç现èãèªçºããããšãå¯èœã§ããããããæçãå«ããäžèš1ã26ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ 骚é«å¢æ®æ§é害ãããã§ãããäžèš1ã27ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ ããããæçããæ倧ã§50åã®ã¢ããé žæ®åºã奜ãŸããã¯ãæ倧ã§30åã®ã¢ããé žæ®åºããã奜ãŸããã¯ãæ倧ã§20åã®ã¢ããé žæ®åºãäŸãã°ãæ倧ã§9åã®ã¢ããé žæ®åºãããªããäžèš1ã28ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ ããããæçããé åçªå·2ãé åçªå·3ãé åçªå·15ãé åçªå·1ãé åçªå·17ãåã³åè¿°ã®ãã¡ã®ããããã®æ©èœççžåäœã§ãã£ãŠãæ倧ã§3åã®ã¢ããé žã眮æãããŠãããåäžãªé åã®ããªããããã§ããæ©èœççžåäœãããªã矀ããéžæããããäžèš1ã29ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ ããããæçããé åçªå·7åã³ãã®æ©èœççžåäœã§ãã£ãŠãæ倧ã§3åã®ã¢ããé žãäŸãã°ãæ倧ã§2åã®ã¢ããé žãäŸãã°ãæ倧ã§1åã®ã¢ããé žã眮æãããŠãããåäžãªé åã®ããªããããã§ããæ©èœççžåäœãããªã矀ããéžæããããäžèš1ã30ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ ããããæçãé åçªå·7ã§ãããäžèš1ã31ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ åèšããªããããããé åçªå·7ã®ã¢ããé žã®é£ç¶é åã奜ãŸããã¯ãé åçªå·7ãå«ããæ倧ã§100åã®ã¢ããé žã奜ãŸããã¯ãæ倧ã§60åã®ã¢ããé žããã奜ãŸããã¯ãæ倧ã§20åã®ã¢ããé žãäŸãã°ãæ倧ã§9åã®ã¢ããé žã®ããªããããã§ãããäžèš1ã32ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ åèšããªããããããé åçªå·2ãé åçªå·3ãé åçªå·15ãé åçªå·1ãåã¯é åçªå·17ã®ã¢ããé žã®ãã¡ã®å°ãªããšã8ã¢ããé žã®é£ç¶é åãå«ããæ倧ã§100åã®ã¢ããé žã奜ãŸããã¯ãæ倧ã§60åã®ã¢ããé žããã奜ãŸããã¯ãæ倧ã§20åã®ã¢ããé žãäŸãã°ãæ倧ã§9åã®ã¢ããé žã®ããªããããã§ãããäžèš1ã33ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ åèšããªããããããé åçªå·2ãé åçªå·3ãé åçªå·15ãé åçªå·1ãåã¯é åçªå·17ãå«ããæ倧ã§100åã®ã¢ããé žãäŸãã°ãæ倧ã§90åã®ã¢ããé žãäŸãã°ãæ倧ã§80åã®ã¢ããé žãäŸãã°ãæ倧ã§60åã®ã¢ããé žãäŸãã°ãæ倧ã§40åã®ã¢ããé žãäŸãã°ãæ倧ã§30åã®ã¢ããé žãäŸãã°ãæ倧ã§29åã®ã¢ããé žã®ããªããããã§ãããäžèš1ã34ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ ã¯ã¯ãã³ããã¯ã¯ãã³æ¥çš®ãããåäœã«ãããã现èãäŸãã°ãé åçªå·16è¥ããã¯é åçªå·1ãå«ããšã¯ãœã³9å€ç°äœCALRãçºçŸãããã现èãåã³/åã¯é åçªå·16è¥ããã¯é åçªå·1ãå«ããšã¯ãœã³9å€ç°äœCALRã®æåãæ瀺ããæåæ瀺现èã«å¯Ÿãã现èå·å®³å¹æãæããT现èã®ç£çãèªçºãããäžèš1ã35ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ ã¯ã¯ãã³ããã¯ã¯ãã³æ¥çš®ãããåäœã«ããããé åçªå·7ãå«ãå€ç°äœJAK2ãçºçŸãããã现èãåã³/åã¯é åçªå·6ã®å€ç°äœJAK2ã®æåãæ瀺ããæåæ瀺现èã«å¯Ÿãã现èå·å®³å¹æãæããT现èã®ç£çãèªçºãããäžèš1ã36ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ 察象ã«ãããèšåºå¿çãèªçºããããšãå¯èœã§ãããèšåºå¿çããå®å®ãéšåå¥å¹ãåã¯å®å šå¯è§£ã«ããç¹åŸŽä»ãããããäžèš1ã37ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ CALRã§ããšã¯ãœã³9å€ç°äœCALRã§ããªãã¿ã³ãã¯è³ªåã¯ããããæçããéžæãããå ç«åãšããŠæŽ»æ§ã®ã¿ã³ãã¯è³ªåã¯ããããæçãããã«å«ããäžèš1ã38ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ JAK2ã§ãJAK2V617Fã§ããªãã¿ã³ãã¯è³ªåã¯ããããæçããéžæãããå ç«åãšããŠæŽ»æ§ã®ã¿ã³ãã¯è³ªåã¯ããããæçãããã«å«ããäžèš1ã39ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ ã¢ãžã¥ãã³ããã现èDNAããŒã¹ã®ã¢ãžã¥ãã³ããæ²¹/çé¢æŽ»æ§å€ããŒã¹ã®ã¢ãžã¥ãã³ãããŠã€ã«ã¹dsRNAããŒã¹ã®ã¢ãžã¥ãã³ããåã³ã€ãããŸãããªã³ãããªã矀ããéžæããããäžèš1ã40ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ ã¢ãžã¥ãã³ããMontanide ISAã¢ãžã¥ãã³ãã§ãããäžèš1ã41ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ ã¢ãžã¥ãã³ããMontanide ISA 51åã¯Montanide ISA 720ã§ãããäžèš42ã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ ã¢ãžã¥ãã³ããMontanide ISA 51ã§ãããäžèš43ã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ ã¢ãžã¥ãã³ããGM-CSFã§ãããäžèš1ã41ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ å ç«åãšããŠæŽ»æ§ã®ããããæçãåã¯åèšå ç«åãšããŠæŽ»æ§ã®ããããæçãã³ãŒãããæ žé žãå«ãæåæ瀺现èãå«ããäžèš1ã45ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ æåæ瀺现èãæš¹ç¶çŽ°èã§ãããäžèš45ã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ æ žé žããäžèš1ã47ã®ããããã«èšèŒã®ãããããã³ãŒããããäžèš2åã¯äžèš3ã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ æ žé žããã¯ã¿ãŒå ã«å«ãŸãããäžèš1ã48ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ ãã¯ã¿ãŒãããŠã€ã«ã¹ãã¯ã¿ãŒåã³çŽ°èãã¯ã¿ãŒãããªã矀ããéžæããããäžèš48ã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ ãã¯ã¿ãŒããT现èåºæ¿æ§ããªãããããã³ãŒãããæ žé žãããã«å«ããäžèš48åã¯49ã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ é åçªå·16è¥ããã¯é åçªå·1ãå«ããšã¯ãœã³9å€ç°äœCALRåã³/åã¯é åçªå·6ã®å€ç°äœJAK2V617FãçºçŸããã骚é«å¢æ®æ§é害ãæ²»çããããã®ãã®ã§ãããäžèš1ã51ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ã
ïŒïŒïŒ äžèš1ã51ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ãåã³ç¬¬2ã®æå¹æåãå«ããããã
ïŒïŒïŒ 第2ã®æå¹æåãå ç«åºæ¿çµæç©ã§ãããäžèš53ã«èšèŒã®ãããã
ïŒïŒïŒ å ç«åºæ¿çµæç©ãIFN-γãå«ããäžèš54ã«èšèŒã®ãããã
ïŒïŒïŒ ãããªãå ç«åºæ¿çµæç©ãã1皮以äžã®ã€ã³ã¿ãŒãã€ãã³ãå«ããäžèš54åã¯55ã«èšèŒã®ãããã
ïŒïŒïŒ ã€ã³ã¿ãŒãã€ãã³ããIL-2åã³/åã¯IL-21ããéžæããããäžèš53ã56ã®ããããã«èšèŒã®ãããã
ïŒïŒïŒ 第2ã®æå¹æåãæããå€ã§ãããäžèš53ã56ã®ããããã«èšèŒã®ãããã
ïŒïŒïŒ æããå€ãååŠçæ³å€ã§ãããäžèš58ã«èšèŒã®ãããã
ïŒïŒïŒ ååŠçæ³å€ããã¢ã¯ããããã¢ã¶ã·ããžã³ãã¢ã¶ããªããªã³ããã¬ãªãã€ã·ã³ãã«ã«ããã©ãã³ãã«ãã·ã¿ãã³ãã·ã¹ãã©ãã³ãã¯ãã©ã ãã·ã«ãã·ã¯ããã¹ãã¡ãããã·ã¿ã©ãã³ãããŠãã«ãã·ã³ããã»ã¿ãã»ã«ãããã·ãã«ãªãžã³ããããœã«ãã·ã³ããšãã«ãã·ã³ããšããã·ãããã«ãã©ãã³ããã«ãªããŠã©ã·ã«ãã²ã ã·ã¿ãã³ãããããã·ãŠã¬ã¢ãã€ãã«ãã·ã³ãã€ãªããã«ã³ãã¬ããªãããããã€ã³ããªã³ãã¡ã¯ãã¬ã¿ãã³ãã¡ã«ãã¡ã©ã³ãã¡ã«ã«ããããªã³ãã¡ããã¬ããµãŒããããããµã³ããã³ããªããµãªãã©ãã³ããã¯ãªã¿ãã»ã«ããã¡ãã¬ãã»ããã¬ããªããããã¢ãŸãããããããã·ããããªã°ã¢ãã³ããã«ã«ãã·ã³ããã³ãã©ã¹ãã³ããã³ã¯ãªã¹ãã³ããã³ãã·ã³ãåã³ããã¬ã«ãã³ããéžæããããäžèš59ã«èšèŒã®ãããã
ïŒïŒïŒ 第2ã®æå¹æåãæçç©è³ªã§ãããäžèš53ã60ã®ããããã«èšèŒã®ãããã
ïŒïŒïŒ æçç©è³ªããã¢ã¢ãã·ãªã³ãããã·ãªã³ãã¢ã·ã¯ããã«ãåã³/åã¯ããã©ãã³ããéžæããããäžèš61ã«èšèŒã®ã¯ã¯ãã³çµæç©ãå«ããããã
ïŒïŒïŒ æäŸãããçµæç©ããåæã«ãåã¯é次çã«æäžããããäžèš53ã62ã®ããããã«èšèŒã®ãããã
ïŒïŒïŒ äžèš1ã52ã®ããããã«èšèŒã®ããããæçãåã³ã¯ã©ã¹Iã®HLAååè¥ããã¯ã¯ã©ã¹IIã®HLAååãåã¯ãã®ãããªååã®æçã®è€åäœã
ïŒïŒïŒ åéäœã§ãããäžèš64ã«èšèŒã®è€åäœã
ïŒïŒïŒ å€éäœã§ãããäžèš64ã«èšèŒã®è€åäœã
ïŒïŒïŒ ããèšåºç¶æ ã«ããåäœã«ãããŠããšã¯ãœã³9å€ç°äœCALRã«å¯ŸããŠåå¿æ§ã®T现èãåã¯JAK2V617Fã«å¯ŸããŠåå¿æ§ã®T现èã®ååšãæ€åºããæ¹æ³ã§ãã£ãŠãè «ççµç¹åã¯è¡æ¶²è©Šæããäžèš64ãã66ã®ããããã«èšèŒã®è€åäœãšæ¥è§Šãããã¹ããããåã³è€åäœã®ãçµç¹åã¯è¡æ¶²çŽ°èãšã®çµåãæ€åºããã¹ãããããå«ãæ¹æ³ã
ïŒïŒïŒ äžèš1ã52ã103ã104ãåã¯107ã108ã®ããããã«èšèŒã®ããããæçã«ç¹ç°çã«çµåããããšãå¯èœã§ããååã
ïŒïŒïŒ æäœåã¯ãã®æçã§ãããäžèš68ã«èšèŒã®ååã
ïŒïŒïŒ T现èå容äœã§ãããäžèš68åã¯69ã«èšèŒã®ååã
ïŒïŒïŒ äžèš68ã70ã®ããããã«èšèŒã®ååã®çµåãé®æããããšãå¯èœã§ããååã
ïŒïŒïŒ ãšã¯ãœã³9å€ç°äœCALRã®çºçŸåã³/åã¯JAK2V617Fã®çºçŸã«ãã£ãŠç¹åŸŽä»ããããèšåºç¶æ ãæ²»çåã¯äºé²ããæ¹æ³ã§ãã£ãŠãåèšèšåºç¶æ ã«ããåäœã«ãæå¹éã®ãäžèš1ã52ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ãäžèš68ã71ã®ããããã«èšèŒã®ååãäžèš97ã102ã®ããããã«èšèŒã®çµæç©ãåã¯äžèš103ã104è¥ããã¯107ã108ã®ããããã«èšèŒã®ãããããæäžããã¹ããããå«ãæ¹æ³ã
ïŒïŒïŒ æ²»çåã¯äºé²ãããèšåºç¶æ ãããšã¯ãœã³9å€ç°äœCALRåã³/åã¯JAK2V617FãçºçŸãããããçŸæ£ã§ãããäžèš72ã«èšèŒã®æ¹æ³ã
ïŒïŒïŒ ãããªãããæ²»çãšçµã¿åãããããäžèš72åã¯73ã«èšèŒã®æ¹æ³ã
ïŒïŒïŒ ãããªãæ²»çããååŠçæ³ãæŸå°ç·æ²»çãå ç«åºæ¿ç©è³ªã«ããæ²»çãéºäŒåæ²»çãæäœã«ããæ²»çãåã³æš¹ç¶çŽ°èã䜿çšããæ²»çãããªã矀ããéžæããããäžèš74ã«èšèŒã®æ¹æ³ã
ïŒïŒïŒ æ²»çåã¯äºé²ãããèšåºç¶æ ããæåæ瀺现èå ã®ãšã¯ãœã³9å€ç°äœCALRã®çºçŸåã³/åã¯JAK2V617Fã®çºçŸãåŒãèµ·ããé害ã§ãããäžèš72ã75ã®ããããã«èšèŒã®æ¹æ³ã
ïŒïŒïŒ åèšé害ã«å¯Ÿãããããªãæ²»çãšçµã¿åãããããäžèš76ã«èšèŒã®æ¹æ³ã
ïŒïŒïŒ ãããªãæ²»çããååŠçæ³ãå ç«åºæ¿ç©è³ªã«ããæ²»çãéºäŒåæ²»çãæäœã«ããæ²»çãåã³æš¹ç¶çŽ°èã䜿çšããæ²»çãããªã矀ããéžæããããäžèš77ã«èšèŒã®æ¹æ³ã
ïŒïŒïŒ ãšã¯ãœã³9å€ç°äœCALRåã¯JAK2V617Fã®å ç«åãšããŠæŽ»æ§ã®ããããæçããåäœåœãã50ÎŒgã500ÎŒgã®ç¯å²ãäŸãã°ã80ÎŒgã300ÎŒgã®ç¯å²ãäŸãã°ã100ÎŒgã250ÎŒgã®ç¯å²ã®çšéã§æäžãããåäœãã奜ãŸããã¯ããã§ãããäžèš72ã78ã®ããããã«èšèŒã®æ¹æ³ã
ïŒïŒïŒ èšåºç¶æ ãæ²»çåã¯äºé²ããããã®å»è¬ã®è£œé ã«ããããäžèš1ã72ã®ããããã«èšèŒã®ã¯ã¯ãã³çµæç©ãäžèš74ã63ã®ããããã«èšèŒã®ããããäžèš68ã70ã®ããããã«èšèŒã®ååãåã¯äžèš89ã96ã®ããããã«èšèŒã®ããããæçã®äœ¿çšã
ïŒïŒïŒ æ²»çåã¯äºé²ãããçŸæ£ãããšã¯ãœã³9å€ç°äœCALRåã³/åã¯JAK2V617FãçºçŸãããããçŸæ£ã§ãããäžèš80ã«èšèŒã®äœ¿çšã
ïŒïŒïŒ ãããªãããæ²»çãšçµã¿åãããããäžèš80åã¯81ã«èšèŒã®äœ¿çšã
ïŒïŒïŒ ãããªãæ²»çããååŠçæ³ãæŸå°ç·æ²»çãå ç«åºæ¿ç©è³ªã«ããæ²»çãéºäŒåæ²»çãæäœã«ããæ²»çãåã³æš¹ç¶çŽ°èã䜿çšããæ²»çãããªã矀ããéžæããããäžèš82ã«èšèŒã®äœ¿çšã
ïŒïŒïŒ æ²»çåã¯äºé²ãããèšåºç¶æ ããæåæ瀺现èå ã®ãšã¯ãœã³9å€ç°äœCALRã®çºçŸåã³/åã¯JAK2V617Fã®çºçŸãåŒãèµ·ããé害ã§ãããäžèš83ã«èšèŒã®äœ¿çšã
ïŒïŒïŒ åèšææã«å¯Ÿãããããªãæ²»çãšçµã¿åãããããäžèš84ã«èšèŒã®äœ¿çšã
ïŒïŒïŒ ãããªãæ²»çããååŠçæ³ãå ç«åºæ¿ç©è³ªã«ããæ²»çãéºäŒåæ²»çãæäœã«ããæ²»çãåã³æš¹ç¶çŽ°èã䜿çšããæ²»çãããªã矀ããéžæããããäžèš85ã«èšèŒã®äœ¿çšã
ïŒïŒïŒ å ç«åãã¢ãã¿ãªã³ã°ããæ¹æ³ã§ãã£ãŠã
a)åäœã«ç±æ¥ããè¡æ¶²è©Šæãçšæããã¹ãããã
b)(i)é åçªå·16åã¯é åçªå·1ãå«ãCALRã®ãšã¯ãœã³9å€ç°äœãäŸãã°ãé åçªå·10ã«ç€ºããããCALRã®ãšã¯ãœã³9å€ç°äœãåã¯
(ii)é åçªå·10ã«ç€ºããããšã¯ãœã³9å€ç°äœCALRã®ãå ç«åãšããŠæŽ»æ§ã®ããããæçã§ãã£ãŠãé åçªå·10ã®ã¢ããé ž361ã411ã®ãã¡ã®å°ãªããšãäžéšãå«ãæçãåã¯
(iii)é åçªå·1ãé åçªå·2ãé åçªå·3ãé åçªå·15ãè¥ããã¯é åçªå·17ãåã¯ãã®æçãããªããå ç«åãšããŠæŽ»æ§ã®ãããããåã¯
(iv)é åçªå·6ã«ç€ºãããJAK2V617Få€ç°äœãåã¯
(v)é åçªå·6ã«ç€ºãããJAK2V617Få€ç°äœã®ãå ç«åãšããŠæŽ»æ§ã®ããããæçã§ãã£ãŠãé åçªå·6ã®ã¢ããé ž617ãå°ãªããšãå«ãæçãåã¯
(vi)åè¿°ã®ãã¡ã®ããããã®æ©èœççžåäœ
ãçšæããã¹ãããã
c)åèšè¡æ¶²è©Šæããã¿ã³ãã¯è³ªåã¯ããããã«ç¹ç°çã«çµåãããæäœãåã¯T现èå容äœãå«ãT现èãå«ããã©ããã決å®ããã¹ããã
ãå«ã¿ã
ããã«ãããåèšã¿ã³ãã¯è³ªåã¯ããããã«å¯Ÿããå ç«å¿çããåèšåäœã«ãããŠæ¹èµ·ããããã©ããã決å®ãã
æ¹æ³ã
ïŒïŒïŒ ããããæçããäžèš1ã52ã®ããããã«èšèŒã®ããããæçã§ãããäžèš87ã«èšèŒã®æ¹æ³ã
ïŒïŒïŒ å€ç°äœCALRã®çºçŸãšé¢é£ããèšåºç¶æ ãäŸãã°ã骚é«å¢æ®æ§é害ã®æ²»çåã¯äºé²ã«ãããŠäœ¿çšããããã®ãé åçªå·16è¥ããã¯é åçªå·1ã®é£ç¶é åã®ãã¡ã®å°ãªããšãäžéšãå«ããå ç«åãšããŠæŽ»æ§ã®ãšã¯ãœã³9å€ç°äœCALRã®ããããæçãåã¯ãã®æ©èœççžåäœã§ãã£ãŠãæ倧ã§3åã®ã¢ããé žã眮æãããŠããããšãé€ããåäžãªé åã®ããªããããã§ããæ©èœççžåäœãåã¯åèšããããæçãã³ãŒãããæ žé žã
ïŒïŒïŒ äžèš1ã52ã®ããããã«èšèŒã®ããããæçã§ãããäžèš89ã«èšèŒã®ããããæçã
ïŒïŒïŒ ããã®æ²»çåã¯äºé²ã«ãããŠäœ¿çšããããã®ãäžèš89åã¯90ã«èšèŒã®ããããæçã
ïŒïŒïŒ ãšã¯ãœã³9å€ç°äœCALRã®çºçŸãšé¢é£ããèšåºç¶æ ãäŸãã°ã骚é«å¢æ®æ§é害ã®æ²»çåã¯äºé²ã«ãããŠäœ¿çšããããã®ãé åçªå·2ãé åçªå·3ãé åçªå·15ãé åçªå·1ãè¥ããã¯é åçªå·17ãå«ããåã¯ãããããªããäžèš89ã91ã®ããããã«èšèŒã®ããããæçãåã¯ãã®æ©èœççžåäœã§ãã£ãŠãæ倧ã§3åã®ã¢ããé žã眮æãããŠããããšãé€ããåäžãªé åã®ããªããããã§ããæ©èœççžåäœãåã¯åèšCALRã®ããããæçãã³ãŒãããæ žé žã
ïŒïŒïŒ å€ç°äœJAK2V617Fã®çºçŸãšé¢é£ããèšåºç¶æ ãäŸãã°ã骚é«å¢æ®æ§é害ã®æ²»çåã¯äºé²ã«ãããŠäœ¿çšããããã®ãé åçªå·7ã®é£ç¶é åã®ãã¡ã®å°ãªããšãäžéšãå«ããå ç«åãšããŠæŽ»æ§ã®JAK2V617Fã®ããããæçãåã¯ãã®æ©èœççžåäœã§ãã£ãŠãæ倧ã§3åã®ã¢ããé žã眮æãããŠããããšãé€ããåäžãªé åã®ããªããããã§ããæ©èœççžåäœãåã¯åèšJAK2V617Fã®ããããæçãã³ãŒãããæ žé žã
ïŒïŒïŒ äžèš1ã52ã®ããããã«èšèŒã®ããããæçã§ãããäžèš93ã«èšèŒã®ããããæçã
ïŒïŒïŒ ããã®æ²»çåã¯äºé²ã«ãããŠäœ¿çšããããã®ãäžèš93åã¯94ã«èšèŒã®ããããæçã
ïŒïŒïŒ JAK2V617Fã®çºçŸãšé¢é£ããèšåºç¶æ ãäŸãã°ã骚é«å¢æ®æ§é害ã®æ²»çåã¯äºé²ã«ãããŠäœ¿çšããããã®ãé åçªå·7ãå«ããè¥ããã¯ãããããªããäžèš93ã95ã®ããããã«èšèŒã®ããããæçãåã¯ãã®æ©èœççžåäœã§ãã£ãŠãæ倧ã§3åã®ã¢ããé žã眮æãããŠããããšãé€ããåäžãªé åã®ããªããããã§ããæ©èœççžåäœãåã¯åèšJAK2ã®ããããæçãã³ãŒãããæ žé žã
ïŒïŒïŒ ãšã¯ãœã³9å€ç°äœCALRãç¹ç°çã«èªèãã现èãå«ãçµæç©ã§ãã£ãŠã奜ãŸããã¯ããšã¯ãœã³9å€ç°äœCALRããæ倧ã§3åã®ã¢ããé žã眮æãããé åçªå·16ã®é£ç¶é åãå«ããçµæç©ã
ïŒïŒïŒ 现èãã现èå·å®³æ§T现èã§ãããäžèš97ã«èšèŒã®çµæç©ã
ïŒïŒïŒ 现èããäžèšã®ããããã«èšèŒã®ããããè¥ããã¯ããããæçãåã¯äžèš103ã104ã«èšèŒã®ããããè¥ããã¯ããããæçããT现èãå«ã现èéå£ãšæ¥è§Šãããããšã«ããåŸããããäžèš97åã¯98ã«èšèŒã®çµæç©ã
ïŒïŒïŒïŒ JAK2V617Fãç¹ç°çã«èªèãã现èãå«ãçµæç©ã§ãã£ãŠã奜ãŸããã¯ãJAK2V617Fããæ倧ã§3åã®ã¢ããé žã眮æãããé åçªå·6ã®é£ç¶é åãå«ããçµæç©ã
ïŒïŒïŒïŒ 现èãã现èå·å®³æ§T现èã§ãããäžèš100ã«èšèŒã®çµæç©ã
ïŒïŒïŒïŒ 现èããäžèš107åã¯108ã«èšèŒã®ããããåã¯ããããæçããT现èãå«ã现èéå£ãšæ¥è§Šãããããšã«ããåŸããããäžèš100åã¯101ã«èšèŒã®çµæç©ã
ïŒïŒïŒïŒ CALRã®é å(é åçªå·9)ãåã¯é åçªå·1ã®é åãå«ãCALRã®ãšã¯ãœã³9å€ç°äœã®é åã®ãã¡ã®50ãŸã§ã®é£ç¶ã¢ããé žãå«ãããåã¯ãããããªãããããã§ãã£ãŠãåèšå€ç°äœããä»»æéžæã§ãé åçªå·10ã®é åãæããåèšé£ç¶ã¢ããé žããé åçªå·1ã2ã3ã15ã16ãåã¯17ã®ãã¡ã®ãããã1ã€ã®é åãå«ã¿ããã奜ãŸããã¯ãåèšé£ç¶ã¢ããé žããé åçªå·1ãé åçªå·2ãé åçªå·3ãåã¯é åçªå·17ãå«ã¿ãä»»æéžæã§ãæ倧ã§1ã10åã®éã®é£ç¶ã¢ããé žãã眮æãäŸãã°ãä¿åç眮æã«ãã眮ãæããããŠãããããããã
ïŒïŒïŒïŒ å ç«åãšããŠæŽ»æ§ã§ãããäžèš103ã«èšèŒã®ããããã
ïŒïŒïŒïŒ äžèš103åã¯104ã«èšèŒã®ããããã䞊ã³ã«ä»»æéžæã§ä¿åå€åã³/åã¯ã¢ãžã¥ãã³ããå«ãå»è¬çµæç©ã
ïŒïŒïŒïŒ ãããå¿ èŠãšããåäœãæ²»çããæ¹æ³ã§ãã£ãŠãäžèš103åã¯104ã«èšèŒã®ãããããåèšåäœã«æäžããã¹ããããå«ãæ¹æ³ã
ïŒïŒïŒïŒ JAK2ã®é å(é åçªå·5)ãåã¯é åçªå·6ã®é åãå«ãJAK2V617Fã®é åã®ãã¡ã®50åãŸã§ã®é£ç¶ã¢ããé žãå«ãããåã¯ãããããªãããããã§ãã£ãŠãåèšé£ç¶ã¢ããé žããé åçªå·7ã®é åãå«ã¿ãä»»æéžæã§ãæ倧ã§1ã10åã®éã®é£ç¶ã¢ããé žãã眮æãäŸãã°ãä¿åç眮æã«ãã眮ãæããããŠãããããããã
ïŒïŒïŒïŒ å ç«åãšããŠæŽ»æ§ã§ãããäžèš107ã«èšèŒã®ããããã
ïŒïŒïŒïŒ äžèš107åã¯108ã«èšèŒã®ããããã䞊ã³ã«ä»»æéžæã§ä¿åå€åã³/åã¯ã¢ãžã¥ãã³ããå«ãå»è¬çµæç©ã
ïŒïŒïŒïŒ ãããå¿ èŠãšããåäœãæ²»çããæ¹æ³ã§ãã£ãŠãäžèš107åã¯108ã«èšèŒã®ãããããåèšåäœã«æäžããã¹ããããå«ãæ¹æ³ã
å®çŸ©ïŒœ
ã¢ãžã¥ãã³ã:æäžãããå ç«åãšããŠæŽ»æ§ã®ãããã/æå/æ žé žæ§ç¯ç©ãšã®æ··åå€ããåèšãããã/æåã«å¯Ÿããå ç«å¿çãå¢å ããããåã¯ããã§ãªãå Žåã¯æ¹å€ããä»»æã®ç©è³ªã
Claims (15)
- 8ã42ã¢ããé žæ®åºé·ã®å ç«åãšããŠæŽ»æ§ã®ããªãããããåã¯è©²ããªãããããã³ãŒãããæ žé žã§ãã£ãŠã該ããªããããããé åçªå·1ãé åçªå·2ãé åçªå·3ãé åçªå·15ãé åçªå·16ãè¥ããã¯é åçªå·17ã®ããããã®ã¢ããé žã®é£ç¶é åãããªãããåã¯é åçªå·1ãé åçªå·2ãé åçªå·3ãé åçªå·15ãé åçªå·16ãè¥ããã¯é åçªå·17ã®ããããã«å¯ŸããŠå°ãªããšã90ïŒ ã®é ååäžæ§ãæãããã®æ©èœççžåäœãããªããäžèšããªããããåã¯æ žé žã
- (a)1皮以äžã®è«æ±é 1èšèŒã®å ç«åãšããŠæŽ»æ§ã®ããªãããããåã¯è©²1皮以äžã®å ç«åãšããŠæŽ»æ§ãªããªãããããã³ãŒãããæ žé žãåã³
(b)ã¢ãžã¥ãã³ããè¬åŠçã«èš±å®¹ããã賊圢å€ãåã³ä¿åå€ã®1皮以äž
ãå«ãçµæç©ã - ãšã¯ãœã³9å€ç°äœCALRãç¹ç°çã«èªèãã现èãã€ã³ã¿ãŒãã€ãã³ãIFN-γãæçç©è³ªãåã³æããå€ãã®1皮以äžãããã«å«ããè«æ±é 2èšèŒã®çµæç©ã§ãã£ãŠã
å Žåã«ãã£ãŠã
(a)æããå€ããã¢ã¯ããããã¢ã¶ã·ããžã³ãã¢ã¶ããªããªã³ããã¬ãªãã€ã·ã³ãã«ã«ããã©ãã³ãã«ãã·ã¿ãã³ãã·ã¹ãã©ãã³ãã¯ãã©ã ãã·ã«ãã·ã¯ããã¹ãã¡ãããã·ã¿ã©ãã³ãããŠãã«ãã·ã³ããã»ã¿ãã»ã«ãããã·ãã«ãªãžã³ããããœã«ãã·ã³ããšãã«ãã·ã³ããšããã·ãããã«ãã©ãã³ããã«ãªããŠã©ã·ã«ãã²ã ã·ã¿ãã³ãããããã·ãŠã¬ã¢ãã€ãã«ãã·ã³ãã€ãªããã«ã³ãã¬ããªãããããã€ã³ããªã³ãã¡ã¯ãã¬ã¿ãã³ãã¡ã«ãã¡ã©ã³ãã¡ã«ã«ããããªã³ãã¡ããã¬ããµãŒããããããµã³ããã³ããªããµãªãã©ãã³ããã¯ãªã¿ãã»ã«ããã¡ãã¬ãã»ããã¬ããªããããã¢ãŸãããããããã·ããããªã°ã¢ãã³ããã«ã«ãã·ã³ããã³ãã©ã¹ãã³ããã³ã¯ãªã¹ãã³ããã³ãã·ã³ãåã³ããã¬ã«ãã³ããéžæãããååŠçæ³å€ã§ããããããŠïŒåã¯
(b)æçç©è³ªããã¢ã¢ãã·ãªã³ãããã·ãªã³ãã¢ã·ã¯ããã«ãåã³ããã©ãã³ããéžæããããããŠïŒåã¯
(c)ã€ã³ã¿ãŒãã€ãã³ãIL-2åã³ïŒåã¯IL-21ã§ããã
äžèšçµæç©ã - CALRè¥ããã¯ãšã¯ãœã³9å€ç°äœCALRåã¯ãããã®å ç«åãšããŠæŽ»æ§ã®æçã§ã¯ãªãå ç«åãšããŠæŽ»æ§ã®ã¿ã³ãã¯è³ªåã¯ããããæçãããã«å«ããè«æ±é 2åã¯3ã«èšèŒã®çµæç©ã
- ã¢ãžã¥ãã³ããã现èDNAããŒã¹ã®ã¢ãžã¥ãã³ããæ²¹ïŒçé¢æŽ»æ§å€ããŒã¹ã®ã¢ãžã¥ãã³ãããŠã€ã«ã¹dsRNAããŒã¹ã®ã¢ãžã¥ãã³ããã¢ã³ã¿ããISAã¢ãžã¥ãã³ããGM-CSFåã³ã€ãããŸãããªã³ãããªã矀ããéžæããã1皮以äžã§ãããå Žåã«ãã£ãŠã¢ã³ã¿ããISAã¢ãžã¥ãã³ããã¢ã³ã¿ããISA-51åã¯ã¢ã³ã¿ããISA-720ã§ãããè«æ±é 2ã4ã®ããããäžé ã«èšèŒã®çµæç©ã
- å ç«åãšããŠæŽ»æ§ã®ããªãããããåã¯è©²å ç«åãšããŠæŽ»æ§ã®ããªãããããã³ãŒãããæ žé žãå«ãæåæ瀺现èãå«ã¿ãå Žåã«ãã£ãŠè©²æåæ瀺现èãæš¹ç¶çŽ°èã§ãããè«æ±é 2ã5ã®ããããäžé ã«èšèŒã®çµæç©ã
- äžèšå ç«åãšããŠæŽ»æ§ã®ããªãããããã³ãŒãããæ žé žããã¯ã¿ãŒå ã«å«ãŸããŠãããå Žåã«ãã£ãŠè©²ãã¯ã¿ãŒãT现èåºæ¿æ§ããªãããããã³ãŒãããæ žé žãããã«å«ããè«æ±é 2ã6ã®ããããäžé ã«èšèŒã®çµæç©ã
- è«æ±é 1ã«èšèŒã®ããªããããè¥ããã¯æ žé žãåã¯è«æ±é 2ã7ã®ããããäžé ã«èšèŒã®çµæç©ã掻æ§æåãšããŠå«ãããšã¯ãœã³9å€ç°äœCALRã®çºçŸã«ãã£ãŠç¹åŸŽä»ããããèšåºç¶æ ãæ²»çåã¯äºé²ããããã®è¬å€ã
- äžèšããªããããããé åçªå·1è¥ããã¯é åçªå·16ã®ã¢ããé žã®é£ç¶é åãåã¯é åçªå·1è¥ããã¯é åçªå·16ã«å¯ŸããŠå°ãªããšã90ïŒ ã®é ååäžæ§ãæãããã®æ©èœççžåäœãããªããè«æ±é 8ã«èšèŒã®è¬å€ã
- äžèšããªããããããé åçªå·2ãé åçªå·3ãåã¯é åçªå·15ã®ã¢ããé žé åãããªããè«æ±é 8ã«èšèŒã®è¬å€ã
- äžèšç¶æ ãããã§ãããè«æ±é 8ã10ã®ããããäžé ã«èšèŒã®è¬å€ã
- äžèšç¶æ ã骚é«å¢æ®æ§é害ã§ãããå Žåã«ãã£ãŠè©²éªšé«å¢æ®æ§é害ãæ¬æ æ§è¡å°æ¿è¡çãåçºæ§éªšé«ç·ç¶çãçæ§èµ€è¡çå¢å çãæ¥æ§éªšé«æ§çœè¡ç åã¯æ ¢æ§éªšé«æ§çœè¡ç ã§ãããè«æ±é 8ã10ã®ããããäžé ã«èšèŒã®è¬å€ã
- ååŠçæ³ãæŸå°ç·æ²»çãå ç«åºæ¿ç©è³ªã«ããæ²»çãéºäŒåæ²»çãæäœã«ããæ²»çãåã³æš¹ç¶çŽ°èã䜿çšããæ²»çããéžæãããæ²»çãšçµã¿åãããŠäœ¿çšããããã®ãè«æ±é 8ã12ã®ããããäžé ã«èšèŒã®è¬å€ã
- äžèšå ç«åãšããŠæŽ»æ§ã®ããªãããããã50ÎŒgã500ÎŒgãå Žåã«ãã£ãŠ80ÎŒgã300ÎŒgãå Žåã«ãã£ãŠ100ÎŒgã250ÎŒgã®çšéã§æäžããããè«æ±é 8ã13ã®ããããäžé ã«èšèŒã®è¬å€ã
- äžèšçµæç©ãåäœã«ãããèšåºé害ã®ãªã¹ã¯ã軜æžããããã«æäžããããè«æ±é 8ã14ã®ããããäžé ã«èšèŒã®è¬å€ã
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201670417 | 2016-06-10 | ||
DKPA201670417 | 2016-06-10 | ||
PCT/DK2017/050190 WO2017211371A2 (en) | 2016-06-10 | 2017-06-09 | Calr and jak2 vaccine compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019517544A JP2019517544A (ja) | 2019-06-24 |
JP2019517544A5 true JP2019517544A5 (ja) | 2020-07-02 |
Family
ID=59284957
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018564211A Withdrawn JP2019517544A (ja) | 2016-06-10 | 2017-06-09 | ïœïœïœåã³ïœïœïœïŒã¯ã¯ãã³çµæç© |
Country Status (8)
Country | Link |
---|---|
US (1) | US20190328857A1 (ja) |
EP (1) | EP3468585A2 (ja) |
JP (1) | JP2019517544A (ja) |
CN (1) | CN109803674A (ja) |
AU (1) | AU2017276498A1 (ja) |
CA (1) | CA3026572A1 (ja) |
IL (1) | IL263574A (ja) |
WO (1) | WO2017211371A2 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019196088A1 (en) * | 2018-04-13 | 2019-10-17 | Syz Cell Therapy Co. | Methods of obtaining tumor-specific t cell receptors |
CR20220220A (es) * | 2019-11-18 | 2022-09-20 | Janssen Biotech Inc | Vacunas basadas en calr y jak2 mutantes y sus usos |
CN111087448A (zh) * | 2019-12-23 | 2020-05-01 | 绎å¡æ©(广å·)å»è¯æéå ¬åž | è¿ç€çžå ³åºå jak2çªåçžå ³æåçèœåå ¶åºçš |
EP4121081A4 (en) * | 2020-03-17 | 2024-04-17 | Memorial Sloan Kettering Cancer Center | HETEROCLITE PEPTIDE VACCINES AGAINST CANCER |
US20230150741A1 (en) | 2020-04-15 | 2023-05-18 | 3M Innovative Properties Company | Compostable compositions, articles and methods of making compostable articles |
CN112168829B (zh) * | 2020-09-24 | 2022-02-15 | ååçå·¥å€§åŠ | æç æ¯è¯ç©åšå¶å€æ²»ç骚é«å¢çåŒåžžç»ŒååŸè¯ç©äžçåºçšåå¶åŸç骚é«å¢çåŒåžžç»ŒååŸè¯ç© |
US20230285548A1 (en) * | 2021-12-16 | 2023-09-14 | Janssen Biotech, Inc. | Vaccines based on mutant calr and jak2 and their uses |
WO2023245139A2 (en) * | 2022-06-17 | 2023-12-21 | Icahn School Of Medicine At Mount Sinai | Mutant calr-peptide based vaccine |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US58767A (en) | 1866-10-16 | John brougjbton | ||
US5554372A (en) | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
AU718311B2 (en) * | 1995-06-05 | 2000-04-13 | Incyte Pharmaceuticals, Inc. | A C5a-like seven transmembrane receptor |
US6096313A (en) | 1996-02-09 | 2000-08-01 | Ludwig Institute For Cancer Research | Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant |
FR2877013A1 (fr) * | 2004-10-27 | 2006-04-28 | Assist Publ Hopitaux De Paris | Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez |
WO2007047653A2 (en) * | 2005-10-17 | 2007-04-26 | Sloan-Kettering Institute For Cancer Research | Synthetic hla binding peptide analogues of mutant v617f jak2 enzyme and uses therefor |
HUE037973T2 (hu) | 2008-04-17 | 2018-09-28 | Io Biotech Aps | Indolamin-2,3-dioxigenáz-alapú immunterápia |
CA2850245C (en) | 2011-10-17 | 2020-04-28 | Herlev Hospital | Pd-l1 based immunotherapy |
US9567641B2 (en) * | 2013-07-03 | 2017-02-14 | Samsung Electronics Co., Ltd. | Combination therapy for the treatment of cancer using an anti-C-met antibody |
SG11201601193TA (en) * | 2013-09-16 | 2016-04-28 | Cemm Forschungszentrum FÃŒr Molekulare Medizin Gmbh | Mutant calreticulin for the diagnosis of myeloid malignancies |
WO2016087514A1 (en) * | 2014-12-02 | 2016-06-09 | Cemm - Forschungszentrum FÃŒr Molekulare Medizin Gmbh | Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies |
CN104561287A (zh) * | 2014-12-26 | 2015-04-29 | å京èŸè¿ªåº·å»åŠæ£éªææéå ¬åž | æ£æµcalråºå 第9å€æŸåçªåçè¯ååæ¹æ³ |
CN105441562A (zh) * | 2015-12-31 | 2016-03-30 | 執èµè¯æç³»ç»(äžæµ·)æéå ¬åž | Carlåºå 猺倱ãæå ¥çªåçæ£æµæ¹æ³åè¯åç |
-
2017
- 2017-06-09 AU AU2017276498A patent/AU2017276498A1/en not_active Abandoned
- 2017-06-09 EP EP17735379.4A patent/EP3468585A2/en not_active Withdrawn
- 2017-06-09 CN CN201780048646.9A patent/CN109803674A/zh active Pending
- 2017-06-09 JP JP2018564211A patent/JP2019517544A/ja not_active Withdrawn
- 2017-06-09 CA CA3026572A patent/CA3026572A1/en not_active Abandoned
- 2017-06-09 WO PCT/DK2017/050190 patent/WO2017211371A2/en unknown
- 2017-06-09 US US16/308,164 patent/US20190328857A1/en not_active Abandoned
-
2018
- 2018-12-09 IL IL263574A patent/IL263574A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019517544A5 (ja) | ||
Wong et al. | Advances in therapeutic cancer vaccines | |
JP5962739B2 (ja) | å ç«èªå°å€ | |
ES2679043T3 (es) | Inmunoterapia de vacuna | |
KR20180129899A (ko) | ì ìíì ë° ìŽê²ì ì¬ì© ë°©ë² | |
JP2011520783A5 (ja) | ||
TW202015719A (zh) | æ°æååå ¶çšé | |
CN111093691A (zh) | èçœèŽšæååå ¶çšé | |
US20200256877A1 (en) | Microbiota Sequence Variants Of Tumor-Related Antigenic Epitopes | |
KR20220110181A (ko) | ë€ì€-ëë©ìž ëšë°±ì§ ë°±ì | |
US20230080443A1 (en) | Immunogenic compounds for cancer therapy | |
JP2023021116A (ja) | ããå ç«çæ³ã®ããã®æ°èŠïœïœïŒïœïŒæšçïœïœïœã¯ã¯ãã³ | |
WO2021074389A1 (en) | Immunogenic compounds for treatment of adrenal cancer | |
JP2023160838A (ja) | æ°èŠïœïœ ïœïœïœïŒïŒã¿ãŒã²ããå ç«çæ³ã¢ãããŒã | |
JP2018517419A (ja) | è€åæ²»çã®ããã®ïœïœ ïœïœïœâïŒæšçåïœïœïœã¯ã¯ãã³ | |
WO2019197563A2 (en) | Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation | |
JP2019533698A (ja) | 䜵çšçæ³ã®ããã®ïœïœïŒæšçæåæ§ïœïœïœã¯ã¯ãã³ | |
JP2018528960A5 (ja) | ||
KR101851666B1 (ko) | ì ê· ctl ìíŒí í 5 ì°ê²° í©íìŽë | |
JP2022501046A (ja) | ã¢ã«ã®ããŒãŒïŒããªãããã | |
JP2022504315A (ja) | 硬骚éé¡ã€ã³ããªã¢ã³ãéçã¯ã¯ãã³ | |
JP2021536247A (ja) | 䜵çšçæ³çšïœïœïœã¯ã¯ãã³ãæšçãšããããªã¢ã³ãã²ã³ | |
CN113966227A (zh) | ç«èäœå以åå¶å | |
RU2805196C2 (ru) | ÐеПаМÑÐžÐ³ÐµÐœÑ Ðž ÐžÑ Ð¿ÑОЌеМеМОе | |
JP2006516258A (ja) | ã¯ã¯ãã³ããã³æè «çã¯ã¯ãã³ã調補ããæ¹æ³ |